Glycan-Cyanovirin-N Interactions and Designed WW Domains: Combining Experimental and Computational Studies by Woodrum, Brian William (Author) et al.
Glycan-Cyanovirin-N Interactions and Designed WW Domains: Combining 
Experimental and Computational Studies
by
Brian William Woodrum
A Dissertation Presented in Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy
Approved July 2014 by the
Graduate Supervisory Committee
Giovanna Ghirlanda, Chair
Kevin Redding
Xu Wang
ARIZONA STATE UNIVERSITY
August 2014
ABSTRACT
 Cyanovirin-N (CVN) is a cyanobacterial lectin with potent anti-HIV activity, 
mediated by binding to the N-linked oligosaccharide moiety of the envelope protein 
gp120. CVN offers a scaffold to develop multivalent carbohydrate-binding proteins with 
tunable specificities and affinities. I present here biophysical calculations completed on a 
monomeric-stabilized mutant of cyanovirin-N, P51G-m4-CVN, in which domain A 
binding activity is abolished by four mutations; with comparisons made to CVNmutDB, in 
which domain B binding activity is abolished. Using Monte Carlo calculations and 
docking simulations, mutations in CVNmutDB were considered singularly, and the 
mutations E41A/G and T57A were found to impact the affinity towards dimannose the 
greatest. 15N-labeled proteins were titrated with Manα(1-2)Manα, while following 
chemical shift perturbations in NMR spectra. The mutants, E41A/G and T57A, had a 
larger Kd than P51G-m4-CVN, matching the trends predicted by the calculations. We also 
observed that the N42A mutation affects the local fold of the binding pocket, thus 
removing all binding to dimannose. Characterization of the mutant N53S showed similar 
binding affinity to P51G-m4-CVN. Using biophysical calculations allows us to study 
future iterations of models to explore affinities and specificities. In	  order	  to	  further	  elucidate	  the	  role	  of	  multivalency,	  I	  report	  here	  a	  designed	  covalent	  dimer	  of	  CVN,	  Nested	  cyanovirin-­‐N	  (Nested	  CVN),	  which	  has	  four	  binding	  sites.	  Nested	  CVN	  was	  found	  to	  have	  comparable	  binding	  af@inity	  to	  gp120	  and	  antiviral	  activity	  to	  wt	  CVN.	  These	  results	  demonstrate	  the	  ability	  to	  create	  a	  multivalent,	  covalent	  dimer	  that	  has	  comparable	  results	  to	  that	  of	  wt	  CVN.
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   WW	  domains	  are	  small	  modules	  consisting	  of	  32-­‐40	  amino	  acids	  that	  recognize	  proline-­‐rich	  peptides	  and	  are	  found	  in	  many	  signaling	  pathways.	  We	  use	  WW	  domain	  sequences	  to	  explore	  protein	  folding	  by	  simulations	  using	  Zipping	  and	  Assembly	  Method.	  We	  identi@ied	  @ive	  crucial	  contacts	  that	  enabled	  us	  to	  predict	  the	  folding	  of	  WW	  domain	  sequences	  based	  on	  those	  contacts.	  We	  then	  designed	  a	  folded	  WW	  domain	  peptide	  from	  an	  unfolded	  WW	  domain	  sequence	  by	  introducing	  native	  contacts	  at	  those	  critical	  positions.
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1. Cyanovirin-N
 1.1. Background on HIV
 Human immunodeficiency virus (HIV) is a retrovirus that can lead to the 
development of acquired immunodeficiency syndrome (AIDS). Bodily fluids transmit 
HIV during sexual contact or blood contact. HIV can also be transmitted from an infected 
mother to her baby at birth. According to the Center for Disease Control (CDC), an 
estimated 1,106,400 people were living in the United States with HIV at the end of 2006.1 
Worldwide, UNAIDS estimated that over 33.4 million people were living with HIV.2 In 
2008, the CDC estimated that nearly 56,300 people in the United States were newly 
infected with HIV.3 With so many people being newly infected with AIDS each year, and 
the number is quite higher for worldwide new infections, it is vitally important to find 
new drug therapies that will inhibit the transmission of HIV. As discussed below, the 
treatment of HIV is extremely difficult because of the virus’ ability to become drug 
resistance very rapidly.
 It is important to understand the life cycle of HIV in order to find targets for drug 
therapy. HIV attaches itself to a host cell, infects the host cell with its RNA, and then uses 
reverse transcriptase to transcribe the RNA into DNA; and then integrates the DNA into 
the host cell’s DNA so that the host cell will translate the viral parts needed for viral 
reproduction. Through the life cycle, there are many targets at which antiviral therapy can 
take place to inhibit HIV (Figure 1).
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Figure 1: The life cycle of HIV. Current targets for approved therapies are cell fusion, 
reverse transcriptase, and maturation. New targets include attachment, receptor binding, 
and integration.4
 Current therapies for treatment of HIV are classified as anti-retroviral therapy (ART) 
and highly active anti-retroviral therapy (HAART). A popular, early therapy that was 
pursued for the treatment of HIV was reverse transcriptase (RT) inhibitors. Many 
derivations of RT inhibitors have been identified to date, including nucleoside RT 
inhibitors (NRTIs), nonnucleoside RT inhibitors (NNRTIs), and nucleotide RT inhibitors 
(NtRTI).5 However, error-prone reverse transcriptase and sheer number of replication 
cycles have led to the selection of drug resistant mutants of HIV.5 Because of this, many 
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other HIV therapy options have been pursued. These include integrase inhibitors and 
protease/maturation inhibitors. Protease inhibitors also have problems overcoming 
resistance, and the genetic basis for this has been well documented.6 A major problem 
with both ART and HAART are that these therapies do not cure the disease and mutants 
with resistance will arise.7
 A recent target for therapy has been disrupting the cell fusion of the HIV virus and the 
host cell. Two such drugs being used are enfuvirtide and tifuvirtide.4 There are many 
steps in attachment and fusion with the host cell to target, however, shown in Figure 2.
 The envelope protein (Env) of HIV mediates recognition of the host cell and then 
fusion to the host cell. Env is comprised of gp120 and a transmembrane protein, gp41; 
which are formed after the cleavage of gp160 and then form a trimer of heterodimers. As 
shown in Figure 2, gp120 forms nonspecific interactions with the target cell membrane. 
This allows specific interactions to occur with the host cell receptor, CD4, which then is 
believed to induce conformational changes in gp120. Depending on the tropism of the 
virus, a co-receptor, either CCR5 or CXCR4, interacts with Env, most likely causing 
further conformational changes in Env. This last conformational change is believed to 
result in the insertion of the gp41 helix bundle into the target cell membrane. Most likely, 
more than one Env trimer is involved in mediating the membrane fusion, as depicted in 
Figure 2.4
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Figure 2. The process in which HIV recognizes and fuses with a host cell presents many 
opportunities to inhibit infection.4
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Figure 3. Electron micrograph of HIV-1 (A). The carbohydrates are stained (dark), 
showing extensive glycosylation concealing the antigenic surface. Molecular model view 
of gp120 trimer, with glycosylated outer domain (green), and complex sugars (red) that 
line the CD4 binding sites (B). Linkages of the oligomannose glycan array shown (C).8
 The heavily glycoslyated protein gp120 plays a large role in HIV’s ability to escape 
the human immune system and in recognition of chemokine co-receptors for host cell 
binding. HIV is able to escape detection by the immune system because the surface 
antigens of Env are glycosylated by host enzymes using “immunologically ‘self’ 
glycans,” or glycans synthesized by the host. Therefore, there is not enough available 
antigenic surface, and the host’s immune system will normally not form antibodies 
against HIV. Figure 3b shows a molecular model of a trimer of gp120, with Figure 3a 
showing a schematic of the oligomannose glycan array on gp120. Targeting the glycan 
array of gp120 removes the chance for HIV to mutate to become resistant to other drugs, 
because the target is now the glycosylation that HIV must use to escape detection from 
the immune system.
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 1.2. Introduction to Cyanovirin-N
  1.2.1. Discovery of cyanovirin-N and antiviral properties
 Cyanovirin-N (CVN) is an 11-kDa protein that was isolated from the cyanobacterium 
Nostoc ellipsosporum.9 It is comprised of 10 1 amino acids and is able to be expressed 
recombinantly in Escherichia coli. CVN was discovered on the basis it was found in an 
extract of cyanobacteria that it exhibited potent inhibition of HIV cytopathy and it was 
thought to be proteinaceous, and there had not been any evidence of antiviral proteins 
from cyanobacteria to date. Further studies had shown that CVN interacted with gp120, 
part of the viral surface envelope glycoprotein.9,10 CVN was found to have antiviral 
activity in the sub-nanomolar range. This is extremely potent and it was also encouraging 
to find that CVN conveyed low cytoxicity to the host cells.
 In order to elucidate the structural determinants of CVN that are responsible for the 
antiviral activity, sequence and numerous structural studies have been performed. 
Sequence studies have shown that CVN is a linear sequence of 101 amino acids that has 
no post-translational modifications and 4 cysteine residues that form intramolecular 
disulfide bonds.11 CVN was also determined to have two domains in the sequence, that 
when compared, showed 32% identity ad 26% conservative changes for an overall 
homology of 58%.12 It was also found that degradation of the N-terminal and the C-
terminal, separately, resulted in excess of 9-fold decrease in potency.12
 The solution structure of CVN showed that the protein consisted of two symmetric 
units: domain A that is comprised of amino acids 1-39 and 91-101, and domain B that is 
comprised of amino acids 40-90.13 Each of these domains has a binding site for the 
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Manα(1-2)Manα linkages on the end of gp120. This quaternary structure of CVN also 
shows a novel fold in which the two domains are pseudosymmetric to each other. Each 
domain has a triple-stranded anti-parallel β-sheet and a β-hairpin, and are joined by two 
helical turns.13
 Unexpectedly, when CVN was crystallized, the structure was found to be a domain-
swapped dimer. When crystallized, the protein had domains that were swapped between 
each symmetrically related monomer. That is such that domain A of one monomer was 
associated with domain B of the other monomer, and vice versa, giving overall 
dimerization as A-B’ and A’-B.14 Figure 4 shows the solution structure of the monomer 
and the x-ray crystal structure of the dimer. As evident from Figure 4, the dimer is 
extremely similar in structure to the monomer; and only the hinge residues, Trp49-Phe54 
that allow the domain-swapping to occur, significantly differ in ϕ and ψ torsional 
angles.15 As it turns out, a small fraction of the dimeric species is present in the 
expression of recombinant CVN, and can be identified through size exclusion 
chromatography.15 After analysis of the mechanistic and thermodynamic contributions to 
domain-swapping, it was determined that the dimer is a “metastable, kinetically trapped 
intermediate” at many pH’s and at room temperature and below.15 It is believed that as 
crystallization occurs, the protein-protein interactions in the formation of the crystal 
lattice structure facilitate the formation of the domain-swapped dimer.15
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Figure 4. Solution structure of wt CVN as a monomer (A), PDB code 1IIY. Residues 
1-39, 91-101 are colored blue, residues 40-90 are colored red, and dimannose is shown in 
each binding pocket. Domain-swapped dimer of wt CVN (B), PDB code 3EZM, shown 
with one monomer colored blue, the other yellow. The two parts of the dimer are nearly 
orthogonal to each other.
  1.2.2. Mutants of Cyanovirin-N
  (This section in part was originally published in Biochemical Society 
Transactions. Brian W. Woodrum, Jason D. Maxwell, Ashini Bolia, S. Banu Ozkan, and 
Giovanna Ghirlanda, The antiviral lectin cyanovirin-N: probing multivalency and glycan 
recognition through experimental and computational approaches. Biochemical Society 
Transactions. 2013; 41: 1170-1176. © the Biochemical Society)
 In cyanovirin-N, multiple binding interactions with the oligomannoside target could 
be achieved by simultaneously engaging both domains A and B in the monomeric form, 
and/or by engaging two or more binding sites in the domain-swapped dimer form. This 
hypothesis is supported by the difference observed in binding linear oligomannosides and 
8
glycosylated gp120. Whereas each domain, A and B, binds di- and tri-mannose 
independently with dissociation constants in the micromolar range, monomeric CVN 
binds gp120 at nanomolar concentrations, suggesting an avidity effect. Further evidence 
of multivalency is the agglutination resulting from the interaction of CVN at micromolar 
concentrations with multidentate mannosides such as Man9 and Man8.16
 To address these issues unequivocally, our lab had previously designed a novel 
mutant, P51G-m4-CVN (Figure 5), which contains a single high-affinity carbohydrate-
binding site (domain B), folds exclusively as a monomer under physiological conditions, 
and is more stable than wt (wild-type) CVN. The protein was designed by merging two 
sets of mutations, four in order to abolish glycan binding to domain A17 and a hinge 
region mutation, P51G, which had been shown to stabilize the monomer and prevent 
domain swapping.19 P51G-m4-CVN was designed to clarify whether the presence of one 
mannose-binding site is sufficient for antiviral activity or whether multivalent 
interactions, either via the two sites on each cyanovirin molecule or via the four possible 
sites on the domain-swapped form, are necessary. This issue had been controversial, 
owing to the difficulties in clearly discriminating between the possible models, and 
complicated further by the slight selectivity of each domain for a different linear 
oligomannoside.16,17,19-22 As designed, P51G-m4-CVN contains a single functional 
carbohydrate-binding site (domain B) and folds exclusively as a monomer under 
physiological conditions; it is possible to obtain the domain-swapped form by unfolding 
and refolding at millimolar protein concentrations.18 The high-resolution X-ray structure 
of the free and dimannose-bound complex revealed important details on the binding 
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mode.18,23 Our lab has previously investigated the interaction of P51G-m4-CVN with 
gp120 by ELISA, revealing a decrease in apparent affinity of ∼100-fold compared with 
wt CVN; high-affinity binding can be rescued by forming the domain-swapped dimer. 
This was the first evidence linking multivalency and high-affinity binding to gp120; we 
further tested the antiviral activity of P51G-m4-CVN, revealing loss of activity at 
concentrations as high as 5 µM. In contrast, wt CVN inhibits HIV with an EC50 of 
approximately 0.1 nM.
Figure 5. (a) Crystal structure of P51G-m4-CVN (PDB code 2RDK)18 with domain B in 
blue and domain A in grey with m4 mutations shown in orange. Only domain B binds 
dimannose, shown with carbons in green and oxygens in red. (b) The hydrogen-bonding 
network to the sugar in domain B (blue) in 2RDK. Hydrogen bonds are cyan, with water 
molecules shown as red dots. The residues that participate in hydrogen-bonding through 
backbone atoms are highlighted in red, and the residues that participate in hydrogen-
bonding through side chains have their side chains highlighted in yellow. (c) Sequence 
10
alignment of wt CVN and P51G-m4-CVN with the mutated residues highlighted in 
orange.
 The complete loss of antiviral activity in P51G-m4-CVN demonstrated the 
importance of multivalent interactions with the viral gp120, confirming one of the 
mechanisms that had been hypothesized for antiviral lectins, as illustrated in Figure 6.24-27 
Our conclusions were corroborated by independent studies of a complementary mutant, 
CVNmutDB, in which the binding site on domain B had been abolished on the background 
of P51G: this mutant is also inactive against HIV.21
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Figure 6. (a) CVN can form a domain-swapped dimer, one monomer is highlighted in 
orange, the other in grey (PDB code 3EZM). (b) The symmetry of binding sites in the 
domain-swapped dimer of wt CVN bound with oligosaccharides colored with green 
carbons, red oxygens and blue nitrogens (PDB code 3GXZ). The binding sites are 30–35 
Å apart. (c) Cartoon representation of the possible binding modes of CVN. CVN is 
depicted as a monomer and a dimer (dimer shown with black hinge region), with domain 
A in red and domain B in blue. Man9 is represented on trimers of gp120 with GlcNAc 
represented as green squares and mannose depicted as orange circles.
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 We then explored whether constructs containing two copies of domain B could 
recover biological function. Mutants S52P-m4-CVN and ∆50Q-m4-CVN, which form 
obligate domain-swapped dimers, restore multivalency because they encompass two 
functional B domains, while containing four mutations that abolish binding in each 
domain A.28 We found that these mutants bind gp120 at nanomolar concentrations, and 
display significant anti-HIV activity. Unfortunately, the hinge mutations resulted in 
reduced thermostability, which affected their performance in antiviral assays performed at 
37˚C; ∆Q50-m4-CVN displayed an EC50 of 320 nM, compared with 0.9 nM observed for 
wt CVN. More complete restoration of activity to levels similar to that of CVN was 
observed in covalent dimers of monomeric constructs containing inactive domain A and 
linked by an intermolecular disulfide bond. In these constructs, multivalency is restored 
by the presence of two intact copies of domainB (BB′) in the dimer, and results in potent 
antiviral activity (IC50 of 6 nM compared with 0.7 nM for wt CVN). A related construct 
containing two copies of intact domain A (AA′) dimerized via domain-swapping has a 
somewhat diminished IC50 of 60 nM; it is unclear whether these differences arise from 
the identity of the intact domains in the dimer (BB′ compared with AA′) or from the 
stability of the dimers (covalent compared with non-covalent dimers).29
 The ability of intact CVN to form domain-swapped dimers30 and higher-order 
oligomers31 suggests that these species may contribute to antiviral activity through glycan 
cross-linking.27 In that case, it may be possible to improve further on the potent antiviral 
activity of CVN by stabilizing dimeric species, and thus augmenting its multivalency. 
Mayo and co-workers designed tandem repeats of CVN to create covalently linked 
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dimers, which form structures highly reminiscent of the domain-swapped dimers 
observed for wt CVN.32 The tandem repeat dimer CVN2L0, which contains two copies of 
wt CVN and thus has all four binding sites intact (A, A′, B, B′), showed improved 
neutralization activity compared with wt CVN; the dimer also showed extensive cross-
clade activity. Obliteration of binding domains within CVN2 demonstrated a linear 
correlation between number of domains and activity. Remarkably, however, no 
improvements in activity were observed for constructs containing three or four copies of 
linked CVN, suggesting that the interdomain distances in the domain-swapped dimer of 
CVN are optimal for binding to gp120.
 1.3. Domain B Binding Pocket Study
 (This section is reproduced by permission from research originally published in 
Biophysical Journal. Ashini Bolia, Brian W. Woodrum, Angelo Cereda, Melissa A. 
Ruben, Xu Wang, S. Banu Ozkan, and Giovanna Ghirlanda, A flexible docking scheme 
efficiently captures the energetics of glycan-cyanovirin binding. Biophysical Journal. 
2014; 105: 1142-1151. © Elsevier Limited)
  1.3.1. Abstract
 Cyanovirin-N (CVN), a cyanobacterial lectin, exemplifies a class of antiviral agents 
that inhibit HIV by binding to the highly glycosylated envelope protein gp120. Here, we 
investigate the energetics of glycan recognition using a computationally inexpensive 
flexible docking approach, backbone perturbation docking (BP-Dock). We benchmarked 
our method using two mutants of CVN: P51G-m4-CVN, which binds dimannose with 
high affinity through domain B, and CVNmutDB, in which binding to domain B has been 
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abolished through mutation of five polar residues to small nonpolar side chains. We 
investigated the energetic contribution of these polar residues along with the additional 
position 53 by docking dimannose to single-point CVN mutant models. Analysis of the 
docking simulations indicated that the E41A/G and T57A mutations led to a significant 
decrease in binding energy scores due to rearrangements of the hydrogen-bond network 
that reverberated throughout the binding cavity. N42A decreased the binding score to a 
level comparable to that of CVNmutDB by affecting the integrity of the local protein struc- 
ture. In contrast, N53S resulted in a high binding energy score, similar to P51G-m4-
CVN. Experimental characterization of the five mutants by NMR spectroscopy 
confirmed the binding affinity pattern predicted by BP-Dock. Despite their mostly 
conserved fold and stability, E41A, E41G, and T57A displayed dissociation constants in 
the millimolar range. N53S showed a binding constant in the low micromolar range, 
similar to that observed for P51G-m4-CVN. No binding was observed for N42A. Our 
results show that BP-Dock is a useful tool for rapidly screening the relative binding 
affinity pattern of in silico-designed mutants compared with wild-type, supporting its use 
to design novel mutants with enhanced binding properties.
  1.3.2. Introduction
 Cyanovirin-N (CVN), a 101 aa lectin isolated from Nostoc ellipsosporum, 
exemplifies a novel class of therapeutic agents that target the surface glycans of HIV and 
other enveloped viruses.8,10,24,33-36 Its potent activity against HIV is mediated by high-
affinity binding to the mannose-rich glycans that decorate the surface of gp120, and 
requires multivalent interactions through two binding domains within the 
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protein.18,23,28,29,32 CVN is unique among lectins in recognizing a glycan unit, 
Manα(1,2)Manα, with high affinity and specificity: glycan array analysis reveals that 
only mannose-rich structures containing the specific glycosidic linkage α-Man-(1,2)-α-
Man are recognized.37,38 For these reasons, the protein is emerging as a convenient model 
system for investigating glycan-protein interactions and testing computational approaches 
to glycan recognition.
 The structure of CVN reveals a novel (to our knowledge) β-sheet fold that comprises 
two quasi-symmetric domains, defined as A (residues 1-38/90-101) and B (residues 
39-89), connected on each side by a short 310 helix. Despite a backbone root mean-square 
standard deviation (RMSD) of 0.76 Å, the two domains are ~25% identical in sequence, 
resulting in slightly different glycan selectivity and affinity. Experimental and 
computational simulation data show a preference for linear trimannose in domain A, and 
a preference for dimannose (Manα(1,2)Manα) in domain B.10,20,23,24,27,33-36,39-43 Domain B 
is generally considered the high-affinity binding site: the reported binding constants are 
in good agreement and show low-micromolar affinity for 
Manα(1,2)Manα.16,18,20,23,28,29,32,39,44 Structural data for CVN and mutants containing an 
intact domain B in the apo and dimannose-bound forms16,18,20,23,27,37,38,41-44, 
complemented by binding studies using oligomannose derivatives45, contributed to 
mapping the key interactions in the glycan recognition event on both the protein and the 
glycan. The origins of the unique specificity and high affinity of wt CVN for dimannose 
are poorly understood.46 In particular, the energetic contribution of backbone versus side-
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chain interactions, and the role of water-mediated hydrogen bonds in determining binding 
affinity are still under debate.
 Here, we analyzed glycan binding by CVN and its mutants by applying a flexible 
docking approach called back-bone perturbation docking (BP-Dock), which is based on 
perturbation response scanning (PRS), a method that combines elastic network models 
with linear response theory.47-50 This approach accurately predicted binding affinity 
patterns of the PDZ domain of PICK1 with various PDZ motifs.50 BP-Dock enabled us to 
integrate backbone and side-chain conformational changes of the protein, as well as the 
flexibility of the glycan ligand, in the docking analysis, which is crucial for accurate 
prediction of binding affinity.50 Compared with computationally expensive traditional 
molecular-dynamics (MD) calculations performed on CVN42,51-53, this method allows for 
rapid in silico screening of a series of mutants.
 For simplicity, we limited our analysis to the high-affinity site, domain B. We 
benchmarked our method by comparing two well-characterized mutants of CVN (Figure 
7): one that comprises an intact domain B (Figure 7 B) and one in which binding to 
domain B has been abolished (Figure 7 C). The computed binding affinities are consistent 
with high-affinity binding for one, and with no binding for the other. Extending our 
docking analysis to single mutants of P51G-m4-CVN, we observed that some mutations 
led to less favorable binding-energy scores, whereas others did not. Based on these 
predictions, we experimentally characterized five mutants and obtained binding affinities 
in agreement with the predictions.
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Figure 7. (A) Crystal structure of P51G-m4-CVN (PDB ID: 2RDK) with dimannose 
bound. (B) Domain B of P51G-m4-CVN, with residues focused on in this study 
highlighted in yellow (blue, nitrogen atoms; red, oxygen atoms). (C) Domain B of 
CVNmutDB (PDB ID: 3CZZ), with residues that differ from those of P51G-m4-CVN 
highlighted in yellow. Domain B of CVNmutDB does not bind dimannose. (D) The 
sequences of the two mutants are shown aligned with domain A (black) and domain B 
(gray). The differences between P51G-m4-CVN and CVNmutDB in domain B are 
highlighted.
 Our work demonstrates that rapid docking can be an efficient tool for predicting 
binding-affinity patterns of various mutants in glycan recognition. However, the method 
relies on accurate prediction of the initial unbound mutant structure. With such tools, it 
should be possible to predict mutations that change affinity and specificity for given 
glycan targets.
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  1.3.3. Materials and Methods
 Benchmark: We analyzed bound mutant structures of P51G-m4-CVN18,23 and 
CVNmutDB 39 in this study. The crystal structures for P51G-m4-CVN (PDB code: 2RDK) 
and CVNmutDB (PDB code: 3CZZ) were retrieved from the Protein Data Bank (http://
www.rcsb.org/pdb).54 These structures were used as templates for binding affinities to 
dimannose sugar in our flexible docking simulations.
 Modeling of single point mutant structures: We first checked the possible impact of 
single point mutations on the local structure, or the overall stability of the protein. By 
analyzing the hydrogen-bond network of each individual site within the binding pocket, 
we found that the side chains of some residues, such as Asn-42 and Thr-57, made critical 
hydrogen bonds with the backbone or side chain of other positions of CVN (Table 1). 
Thus, mutating these positions to Ala could alter the stability or lead to local structural 
change. To capture those effects, we introduced the point mutations into the x-ray 
structure via Swiss PDB Viewer55, and performed short (3 ns) replica-exchange MD 
(REMD) simulations to obtain well-equilibrated mutant models. The initial point mutant 
structure was seeded into the REMD56 simulation, and the temperature of the replicas 
ranged from 270 K to 450 K. Replica spacing was set such that the swap likelihood 
between replicas approached 0.45. The AMBER force field (ff99SB)57 with a generalized 
Born implicit solvent58 model and a solvent-accessible penalty term of 5 cal/mol Å was 
used. An α-carbon covariance matrix was calculated from a 1 ns window of the trajectory, 
and the convergence was checked by the observed high correlation between the slowest 
fluctuation profiles of the two successive windows. After clustering the snapshots of the 
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lowest replica, we used the most dominant structure (i.e., the lowest free-energy state) as 
the predicted mutant model structure.
Table 1. Inter residue hydrogen bond network in P51G-m4-CVN for the specific Domain 
B residues considered in the study.
Residue #
Donor 
Residue
Donor 
Atom
Acceptor 
Residue
Acceptor 
Atom
H-bond 
distance
41
GLU41 N LYS48 O 2.853
LYS48 N GLU41 O 2.902
42
ASN42 ND2 THR57 OG1 2.908
ASN42 ND2 LYS74 O 2.902
GLY45 N ASN42 OD1 2.831
57
THR57 N PHE54 O 3.062
ASN42 ND2 THR57 OG1 2.908
LYS74 N THR57 O 2.973
76 ARG76 N ASP44 OD1 2.901
78 GLN78 N THR75 O 2.889
53
ASN53 N ASN37 O 2.926
ASN53 ND2 ASN53 OD1 3.081
GLU56 N ASN53 O 3.136
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 PRS: When a ligand (i.e., dimannose sugar) approaches a receptor (CVN mutants), it 
exerts force on the binding site, inducing conformational changes. In this work, as a first-
order approximation, we mimicked this by applying small random forces on the protein 
and then computing the displacement of each residue through PRS.47,59 As a matter of 
fact, the most intriguing aspect of the BP-Dock approach is that it generates a wide range 
of binding-induced conformations realized in nature by exerting random unit forces on 
each residue in the sequence without the presence of ligand. This enabled us to integrate 
the conformational changes of the receptor (CVN mutants) in the docking analysis, which 
in turn increased the accuracy of the binding predictions. Thus, ensembles for P51G-m4-
CVN, CVNmutDB, and the individual domain B mutant models were obtained by PRS. 
PRS is a coarse-grained approach that couples elastic network models with linear 
response theory.47,49,60 Previously, we have shown that PRS can 1) capture 
conformational changes upon binding47, 2) identify key residues that mediate long-range 
communication and find allosteric pathways49, and 3) discriminate disease-associated 
mutants from neutral ones.61 We compared the dynamics of PRS, which is based on a 
coarse-grained approach, with those obtained from all-atom MD simulations, and these 
two estimates showed high correlations.49,61 However, PRS requires four orders of 
magnitude less CPU time than MD simulations. Furthermore, although convergence is a 
bottleneck for MD simulations of larger proteins, it is not an issue in the case of PRS. 
Therefore, PRS is a fast and efficient approach to incorporate backbone flexibility48,49,62, 
which most of the conventional docking protocols cannot do because it is a 
computationally expensive and difficult procedure.
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 In the model, the protein structure is viewed as a 3D elastic network in which the Cα 
atom acts as the nodes and identical springs connect the interacting α-carbons. We 
applied a random unit force, F, in a random direction to the α-carbon atom of each residue 
one at a time (i.e., perturbation of a single residue in the chain with a random Brownian 
kick) sequentially along the chain. The perturbation cascaded through the residue 
interaction network of the protein and caused other amino acid positions to respond. By 
using the PRS method, we computed this fluctuation response as a profile, in both 
direction and magnitude. Thus, the response vector, ∆R, gave the deviation of each 
residue from its mean position in the x, y, and z directions upon perturbation. This 
procedure indeed mimicked the natural process of protein binding interactions in a cell as 
a first approximation, since an approaching ligand applies forces on the receptor protein, 
inducing conformational change. To minimize the effects of randomness, we performed 
this procedure 10 times to ensure that the force applied was isotropic and the response 
vector was averaged. These response fluctuation profiles were used to generate low-
resolution multiple receptor conformations (MRCs) based on Cα atoms. If ∆F is a 3N × 1 
vector that contains the components of the externally applied force on the selected 
residues, and H is the Hessian, a 3N × 3N matrix composed of the second derivatives of 
the potential with respect to the components of the position vectors, we can calculate the 
response of the elastic network of residues using Eq. 1:
ΔR[ ]3N×1 = H[ ]3N×3N( )
−1
ΔF[ ]3N×1  (1)
where ∆R is the 3N-dimensional vector of the response fluctuations of all the residues.
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 To derive the perturbed structure, we calculated the final perturbed coordinates for 
each residue as follows:
Rper!" #$3N×3N = R0[ ]3N×1 +α ΔR[ ]3N×1  (2)
where R0 is the vector showing initial coordinates of the residues before perturbation, and 
a is a scaling factor with a value of 50. The arbitrary value of 50 was chosen such that it 
could yield structures in a range of 0.5-2.0 Å RMSD from the original (unperturbed) 
crystal structure.62,63
 The perturbed structures were then clustered to discard similar conformations 
generated from the perturbations on different residues in the protein. The perturbed 
structures generated from PRS varied from each other and had a backbone RMSD of 
0.58-2.15 Å relative to the initial structure. Once the backbone was perturbed, coarse-
grained conformations were obtained by integrating the response fluctuation profile into 
the original Cartesian coordinates; the side chains were derived from the original 
unperturbed structure. An all-atom minimization of these structures was done using the 
AMBER package64,65 to account for the fluctuation in the side chains upon perturbation 
on the backbone of the protein and to relieve strain in the system. Another way to couple 
the side-chains to the perturbed backbone conformations is to update the side-chain 
positions using the internal coordinates of the initial structure and then follow up by 
energy minimization. We tested this approach for 2RDK and the E41A and E41G 
mutants. However, the RMSD between the conformations obtained after minimization 
with and without updated internal coordinates were in the range of 0.26-0.49 Å for 
23
2RDK, 0.03-0.2 Å for E41A, and 0.27-0.43 Å for E41G. We also observed that the 
docking results did not show any significant difference compared with results from the 
minimization approaches discussed above (Table 2). This could be because side-chain 
conformations are again repacked using either rotamer trials or a full combinatorial 
search in RosettaLigand.66,67
 
Table 2. Docking results for two methods of all-atom minimization to include side chain 
position to the perturbed backbone conformations for 2RDK, E41A and E41G mutant.
Using updated Internal 
Coordinates
Without using updated Internal 
Coordinates
Protein
Rosetta Score
(kcal/mol)
X-score
(kcal/mol)
Rosetta Score
(kcal/mol)
X-Score
(kcal/mol)
2RDK -17.25 -7.58 -17.27 -7.51
E41A -13.3 -6.55 -13.41 -6.23
E41G -14.49 -6.9 -14.12 -6.64
 Docking with RosettaLigand: An ensemble docking using PRS-generated 
conformations was performed with RosettaLigand.66,67 The docking simulations for each 
structure in the ensemble were performed using the RosettaLigand protocol in the 
ROSETTA package. RosettaLigand is a method that was specifically developed for 
docking ligands into protein-binding sites. This method incorporates ligand flexibility by 
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changing torsional angles and the backbone of the ligand, whereas the whole protein is 
held fixed throughout the docking simulation. In each case, the coordinates of the 
dimannose sugar were taken from the crystallographic complex of 2RDK and were 
treated as a single residue. The ligand was represented as a set of discrete conformations 
in the docking procedure, ensuring that the ensembles spun a maximal range of the 
conformational space.67 In this study, we perturbed the ligand position and orientation 
randomly with the translation of mean 0.1 Å and rotations of mean 3˚, respectively. The 
rigid-body orientation and side-chain χ angles of the ligand were optimized using the 
gradient-based Davidson-Fletcher-Powell algorithm.66,67 Each docking trajectory 
consisted of 50 of the Monte Carlo minimization cycles, and we computed 10,000 
trajectories to generate a comprehensive ensemble of conformations of the receptor-
glycan complex for each protein. The formation of a distinct binding funnel in energy 
score/RMSD plots was considered as an indication of successful docking, and the final 
docked conformations were selected based on the lowest free-energy pose in the protein-
binding site. The lowest free-energy pose had the lowest Ligsum score among all other 
docking poses (Ligsum is a RosettaLigand scoring function composed of five energy 
terms: attractive, repulsive, solvation, hydrogen bonding, and coulombic).66,67 The overall 
flexible docking approach is outlined in Figure 8. The binding energies of the bound 
complexes with the lowest Ligsum score were evaluated with X-Score. X-Score is an 
empirical scoring function that was developed to rerank the protein-ligand complex and 
give a more accurate estimate of the binding free energies, which have been found to 
correlate with the experimental binding constants.68
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 Protein cloning, expression, and purification: Mutagenic primers were used to 
introduce the E41A, E41G, T57A, N42A, and N53S single mutations into a P51G-m4-
CVN sequence in a pET26b(+) vector and then transformed into BL21(DE3) cells 
(Novagen, Madison, WI). Proteins were expressed as previously described.18,23 Briefly, 
100 mL cell cultures were incubated overnight at 37˚C, and then 10 mL of this culture 
was added to a 1 L of lysogeny broth (LB). For NMR experiments, a modified M9 
minimal media containing 15NH4Cl (Cambridge Isotope Laboratories, Andover, MA) as 
the sole nitrogen source was used in place of LB. Cells were induced with addition of 1 
mM isopropyl β-D-1-thiogalactopyranoside when the OD600 reached 0.8 and were grown 
overnight at 37˚C, and harvested via centrifugation. The cell pellet was lysed by 
sonication and the insoluble fraction was solubilized using an 8 M urea buffer. The 6× 
histidine-tagged proteins were purified on a GE HisTrap HP column (GE Healthcare Bio-
Sciences, Piscataway, NJ) using a Bio-Rad EconoPump (Bio-Rad, Richmond, CA) under 
denaturing conditions. Proteins were refolded by dialysis into a 2 M urea buffer, pH 8.0, 
at room temperature for 12 h, and then overnight into 10 mM Tris, 100 mM NaCl, pH = 
8.0, replacing the Tris buffer once. The protein secondary structure and stability were 
verified by circular dichroism (CD) on a JASCO J-815 CD spectrometer (JASCO, 
Easton, MD). Temperature denaturation experiments were performed by following the 
molar ellipticity at 202 nm of samples containing 20 µM protein in 15 mM potassium 
phosphate; samples were heated over a range of 4–90˚C at 1˚C/min with a data pitch of 
0.5˚C.
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Figure 8. Flow chart of flexible docking method. In our flexible docking approach using 
PRS model, we generated an ensemble of receptor conformations through several steps: 
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(i) sequentially exerting random external force on each single-residue of the CVN 
mutants, (ii) calculating the response fluctuation vector using Perturbation Response 
Scanning (PRS) method, (iii) constructing the low resolution deformed structures (i.e. 
backbone) using the response vectors after each single residue perturbation, (iv) 
clustering the perturbed conformations using k- clustering method, and (v) all-atom 
minimization of each clustered conformation. Once the multiple receptor conformations 
(MRCs) ensemble was completed, we performed a docking simulation using the 
RosettaLigand option in the ROSETTA package for each minimized structure in the 
ensemble. (vi) Lastly, the binding energies of the CVN-dimannose complexes with the 
lowest Ligsum score were evaluated with X-Score. 
 NMR titrations: Purified 15N-labeled protein was buffer exchanged by gel filtration 
with a GE HiLoad 16/600 Superdex 75 pg column (GE Healthcare Bio-Sciences) on an 
Agilent 1260 BIO-inert HPLC system (Agilent Technologies, Santa Clara, CA) into 20 
mM sodium phosphate buffer, pH 6.0. Fractions containing the monomer of the protein 
were pooled and concentrated using Amicon Ultracel-3K centrifugal filters (Millipore, 
Billerica, MA) to 300 µM protein.
 Aliquots from a stock solution of 2α-mannobiose (Sigma Aldrich, St. Louis, MO) 
were titrated into the protein. 1H-15N heteronuclear single quantum coherence (HSQC) 
spectra were obtained on a Varian Innova 500 MHz spectrometer equipped with a room-
temperature triple-resonance probe at gradually increasing molar ratios of ligand to 
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protein. Chemical shifts were observed and the ∆δ were determined according to Eq. 
369,70:
Δδ = ∆ δHN( )2 + 0.17×∆ δN( )2#$ %&
12
 (3)
The chemical shifts were plotted against the molar ratio ([ligand]/[protein])
and fitted to Eq. 4:
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  1.3.4. Results
 Our analysis focused on domain B, which has higher affinity and specificity for 
dimannose (Manα(1,2)Manα) in wt CVN, and for which extensive mutational analysis is 
available. We used two engineered forms of CVN, P51G-m4-CVN and CVNmutDB, which 
present the two extremes of the binding affinity range: P51G-m4-CVN contains a wild-
type (wt) domain B and thus binds dimannose with high affinity18,23, whereas CVNmutDB 
contains an impaired domain B and thus does not bind dimannose at concentrations as 
high as millimolar21. P51G-m4-CVN and CVNmutDB each contain a P51G mutation in the 
hinge region that stabilizes the monomeric form relative to the domain-swapped form of 
CVN.30 The two mutants have been thoroughly characterized, with crystal structures 
available for CVNmutDB 39 and for P51G-m4-CVN in its apo and bound forms.18,23
 Using the crystallographic coordinates as a starting point, we generated ensembles of 
binding-induced conformations by subjecting each protein to PRS. Specifically, we first 
obtained backbone conformational changes upon perturbing different positions with a 
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random force. We generated the full-atom models by adding the side chains and 
performing an all-atom minimization for each conformation in the ensemble. We used 
RosettaLigand to dock the dimannose ligand into the cavity or binding pocket for each 
structure in the ensemble, and scored the lowest-energy poses as described in Materials 
and Methods. The binding energy of dimannose to domain B of P51G-m4-CVN 
calculated by X-Score is -7.58 kcal/mol and the RMSD of the ligand obtained from the 
lowest-energy docked pose is only 0.19 Å. In contrast, analysis of CVNmutDB shows a 
drastic change in the binding energy making it less favorable (-4.68 kcal/mol), 
corresponding to a change in dissociation constant of four orders of magnitude, and a 
ligand RMSD of 0.38 Å obtained from the lowest-energy docked pose. Figure 9 
compares the binding profiles of P51G-m4-CVN and CVNmutDB for dimannose, and the 
docking profile observed for P51G-m4-CVN indicates a well-converged distinct binding 
funnel. In contrast, CVNmutDB shows a poor docking profile in which energetically 
degenerate structures have high RMSDs.
30
Figure 9. The RosettaLigand energy scores (in kcal/mol) versus RMSD of the docked 
complex for CVN mutants and dimannose sugar. P51G-m4-CVN is shown in blue circles 
and CVNmutDB in red squares. The funnel shape of the graph indicates good docking for 
P51G-m4-CVN. In agreement with experiments P51G-m4-CVN-dimannose has 
significantly low binding energy score (-17.25 kcal/mol) while the complex of CVNmutDB 
(-9.28 kcal/mol) does not.
 Next, we analyzed each residue’s energetic contribution to binding by systematically 
mutating each position in P51G-m4-CVN to the corresponding amino acid in CVNmutDB: 
Glu-41, Asn-42, Thr-57, Arg-76 were changed to Ala, and Gln-78 was changed to Gly. 
We also mutated residue 41 to glycine, which is the most common substitution at that 
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position in the CVN-homologous family of proteins, CVNH.37,71 In addition to the 
positions mutated in CVNmutDB, we mutated N53, which lines the binding pocket and 
interacts with the glycan, to serine, because serine is the most common substitution at this 
position in CVNH.37,71
Table 3. Binding energy scores (Ebind) evaluated from X-Score along with corresponding 
RMSDs of the ligand (RMSDligand) and protein side chain positions in the binding site 
(RMSDsidechain) for various CVN mutants are shown. Higher negative values indicate a 
higher binding affinity prediction. Proteins are ordered by decreasing experimental Kd 
values.
Protein RMSDligand (Å)
RMSDsidechain 
(Å)
Xscore Ebind 
(kcal/mol) Experimental Kd
P51Gm4CVN 0.19 0.189 -7.58 low µM
N53S 0.88 1.365 -7.06 low µM
R76A 1.06 1.036 -6.9 NA
Q78G 0.98 0.845 -6.85 NA
E41G 0.82 1.261 -6.82 389 ± 73 µM
E41A 0.74 1.155 -6.7 541 ± 118 µM
T57A 0.99 1.08 -6.46 low mM
N42A 1.08 1.808 -5.37 no binding
CVN(mutDB) 0.38 1.866 -4.68 no binding
 In the absence of crystal structures for the mutants, we generated starting models by 
introducing the individual point mutations into the coordinates of P51G-m4-CVN and 
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performing a short REMD run (3 ns). Starting from the most dominant structure of the 
lowest-temperature REMD run (i.e., the structure with the lowest free energy), we 
applied our flexible docking approach to each mutant (see Materials and Methods for 
details). The mutations at positions 41, 42, and 57 resulted in decreased affinity compared 
with that of P51G-m4-CVN ( Table 3). Position 42 accounts for most of the loss of 
binding energy between the intact domain B in P51G-m4-CVN and the defective domain 
B in CVNmutDB: the X-Score binding energy of N42A (-5.37 kcal/mol) is in close 
proximity to the non-binder CVNmutDB (i.e., -4.68 kcal/mol). This drastic loss in binding 
energy score may indicate the critical role of N42 in stabilizing the structure of the 
binding pocket. The side chain of N42 forms hydrogen bonds to the backbone of 
neighboring residues (Table 1); further, this position is very well conserved in the CVNH 
family.37,68 T57A, E41A, and E41G also showed a significant decrease in binding affinity, 
albeit not as drastic as that observed for N42A. In contrast, the binding energy score of 
N53S mutant (-7.06 kcal/mol) is comparable to that of P51G-m4-CVN (-7.58 kcal/mol). 
To verify the accuracy of our predictions, we recombinantly expressed E41A, E41G, 
T57A, N42A, and N53S on the background of P51G-m4-CVN18,23, and subjected them to 
experimental characterization.
 Effect of single point mutations on fold and stability of CVN: We confirmed that the 
mutants are monomers, similar to the parent construct, using size exclusion 
chromatography. The elution profiles of P51G-m4-CVN and the mutants each exhibit a 
main peak at 89 mL, which accounts for over 80% of the total protein; small peaks at 70 
mL correspond to dimer (Figure 10). We assigned monomer and dimer peaks by 
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comparing the elution profiles with those of recombinant wt CVN, in which the ratio of 
domain-swapped dimer to monomer is ~40:60.23,30
Figure 10. Elution profile of gel filtration of the mutants used in this study: (A) E41A, 
(B) E41G, (C) P51G-m4-CVN (D) T57A, (E) N42A, and (F) N53S. Monomer fractions 
were collected and used for circular dichroism studies and 1H-15N HSQC experiments.
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 The mutations do not affect the overall secondary and tertiary structure of P51G-m4-
CVN, as assessed by CD spectroscopy and 2D-NMR. The CD spectra of the mutants are 
identical to that of P51G-m4-CVN, indicating mainly β structure, with a characteristic 
minimum at 212 nm and maximum at 190 nm (Figure 11). The 1H-15N HSQC correlation 
spectra of isotopically labeled mutants show that the backbone amide resonances are well 
dispersed in both dimensions and resemble the spectrum of P51G-m4-CVN (Figure 13, 
P51G-m4-CVN; Figure 14, E41A and E41G, red spectra; Figures 15-17 for N42A, T57A, 
and N53S, respectively). Taken together, the spectroscopic results demonstrate that the 
mutants display the hallmarks of native proteins, and are consistent with the conservation 
of the CVN fold.
 We assessed the thermodynamic stability of each mutant by thermal denaturation, 
monitoring the loss of secondary structure at increasing temperatures from 4˚C to 90˚C 
by CD at 202 nm, the wavelength at which the largest change is observed between folded 
and unfolded spectra. The thermal denaturation of wt CVN and its mutants is not 
reversible, which precludes a rigorous analysis of the folding thermodynamics. It is 
possible, however, to compare the thermal denaturation profiles of a series of mutants and 
calculate the apparent midpoint of the melting transitions (Tm). The melting curves of the 
mutants (Figure 12) show that, with the exception of T57A and N42A, the single point 
mutations do not affect protein stability significantly. The apparent melting points Tm are 
shown in Table 4.
35
Figure 11. The near UV circular dichroism spectra of the mutants (A) E41A, (B) E41G, 
(C) P51G-m4-CVN, (D) T57A, (E) N42A, and (F) N53S are shown. All the proteins 
show the characteristic minimum at 212 nm and maximum at 190 nm expected of 
cyanovirin-N mutants.
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Figure 12. Thermal denaturation profiles of E41A (red circles), E41G (black squares), 
N53S (green triangles), T57A (blue upside down triangles), and N42A (orange 
diamonds). The unfolding transitions were monitored at 202 nm from 4 to 90˚C using 20 
µM protein in 15 mM potassium phosphate. The melting points are 53˚C, 55˚C, 53˚C, 
50.6˚C, and 48˚C, respectively.
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Table 4. Melting temperatures of the proteins used in this study are outlined. The proteins 
unfold irreversibly, preventing a rigorous analysis of folding thermodynamics.
Protein Tm (˚C)
P51G-m4-CVN 59
E41G 55.3
E41A 53.4
N53S 53.6
T57A 50.6
N42A 48.2
 Binding to dimannose (Man2): We used 2D-NMR spectroscopy to quantify the 
binding of dimannose to P51G-m4-CVN and each of the mutants, by monitoring the 
changes in chemical shift of the backbone amide signals in uniformly labeled proteins 
upon addition of ligand through 1H-15N-correlation spectroscopy (HSQC). This technique 
is particularly well suited for measuring dissociation constants in the mid- to high-
micromolar range72. Titrations were carried out by adding dimannose from a stock 
solution up to at least a 15 molar equivalent in 300 µM protein. A comparison of the 
1H-15N HSQC spectra of the P51G-m4-CVN before (black) and after (red) addition of 
12.5 molar equivalents of dimannose is reported in Figure J. The 1H-15N HSQC spectra 
resulting from the titration of increasing amounts of dimannose (red to black color) into 
E41A and E41G are shown in Figure JJ, A and B, respectively. The binding isotherms 
derived by plotting changes in normalized chemical shifts (∆δ, ppm) of selected 
38
resonances as a function of added dimannose are shown in Figure 14, C and D. As 
expected, P51G-m4-CVN bound tightly to dimannose, and the changes in chemical shift 
signals saturated upon addition of slightly more than one equivalent. In contrast, addition 
of dimannose to E41A and E41G resulted in much weaker binding. The monitored 
chemical shift changes reached saturation only upon addition of several excess 
equivalents of dimannose (5.5 molar equivalents). We calculated the equilibrium 
dissociation constants (Kd) for E41A and E41G by analyzing the changes in chemical 
shifts versus ligand concentration for several resonances, as described in Materials and 
Methods. This analysis yielded Kd values of 541 ± 118 µM for E41A, and 389 ± 74 µM 
for E41G. For T57A, the chemical-shift changes were initially small (<2 molar 
equivalents) and did not reach saturation even after the addition of 15 molar equivalents 
(Figure 15). This behavior suggests a Kd in the low millimolar range. N42A did not show 
any binding to dimannose, as no change in chemical shift was observed in molar 
equivalents up to 20 (Figure 16). In contrast, binding of dimannose to P51G-m4-CVN 
displayed the hallmark of tight binding and occurred in fast-to-intermediate exchange 
mode in the NMR timescale. This behavior prevented an accurate determination of Kd by 
NMR. Consistent with the computational predictions, N53S behaved similarly to P51G-
m4-CVN, and binding was in intermediate exchange (Figure 17). In both cases, analysis 
of the spectra revealed that the protein was saturated upon addition of one equivalent of 
dimannose, and further addition of ligand did not result in changes in the signals.
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Figure 13. 1H-15N heteronuclear single quantum coherence (HSQC) spectra of P51G-m4-
CVN without dimannose (black) and with 12.5 molar equivalents of dimannose (red).
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Figure 14. 1H-15N heteronuclear single quantum coherence (HSQC) spectra of E41A (A) 
and E41G (B) from titrations with increasing amounts of dimannose (red to black). 
Resonances are well dispersed and resemble that of the P51G-m4-CVN spectrum, 
indicating the two mutants are well folded. Example plots and fitting of molar equivalents 
versus normalized peak shift are shown for a single resonance (E41A in C; and E41G in 
D). Average Kd from the fits for E41A and E41G are 541 µM and 389 µM, respectively.
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Figure 15. T57A 1H-15N HSQC spectra with increasing molar equivalents of dimannose 
are shown overlaid. Inset shows blown up view of the change in chemical shift for one 
signal, with increasing molar equivalents shown with red arrow. T57A binds dimannose 
at an appreciably larger Kd than P51G-m4-CVN.
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Figure 16. N42A 1H-15N HSQC spectra at 0 molar equivalents dimannose and 20 molar 
equivalents dimannose are overlaid. The two spectra are identical, signifying that N42A 
does not bind dimannose.
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Figure 17. N53S 1H-15N HSQC spectra with increasing molar equivalents of dimannose 
are shown overlaid. Inset shows blown up view of the change in chemical shift for one 
signal. N53S was found to be in intermediate exchange, suggesting tight binding.
  1.3.6. Discussion
 Computationally intensive explicit-solvent MD simulations along with Poisson-
Boltzmann-based calculations have been used to evaluate binding free energies and 
analyze binding interaction networks, using dimannose and trimannose as ligands. Most 
computational studies have focused on wt CVN40,42,73 and P51G-m4-CVN.43,74 The 
calculated binding energies, in general, reproduced experimental values reported in the 
literature. Explicit-solvent MD simulations indicated the critical role of water and the 
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flexibility of the binding pocket in the binding free energy calculations42, which were 
later confirmed experimentally.18,23 These computational studies showed that several 
hydrogen-bond interactions originate from the backbone amides and carbonyl 
moieties43,74; however, some side-chain hydrogen-bond interactions were also observed, 
especially in α-Man-(1,2)-α-Man-(1,2)-α-Man (trimannose) recognition.73
 Despite the wealth of structural and computational data available for wt CVN and its 
mutants, the role of main-chain interactions versus side-chain interactions in stabilizing 
CVN-dimannose complexes remained unclear. Here, we extended our flexible docking 
protocol to the analysis of dimannose recognition in CVN, using two engineered variants 
(P51G-m4-CVN and CVNmutDB) as benchmarks. We generated backbone-perturbed 
conformations of CVN mutants by applying random unit forces to individual residues in 
a sequential manner. We then performed an all-atom minimization after adding the side 
chains to the backbone-perturbed structures to account for any rotamer changes of the 
side chains and to relieve any strain in the structure, as perturbations on the backbone can 
lead to significant changes in the orientation of the side chains. To understand the drastic 
decrease in binding affinity of CVNmutDB relative to P51G-m4-CVN, we analyzed the 
hydrogen-bond network in the lowest-energy docked poses of P51G-m4-CVN-dimannose 
and CVNmutDB-dimannose using Chimera with a cutoff of 4.0 Å. This approach is 
commonly used in docking studies to roughly estimate critical ligand-receptor 
interactions.75 The network for the P51G-m4-CVN-dimannose complex comprises of 
main-chain nitrogen atoms of Asn-42 and Asp-44 as donors; main-chain oxygen atoms of 
Asn-42, Ser-52, Asn-53, and Lys-74 as acceptors; and side-chain Oγ of Thr-57 as both 
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acceptor and donor (Figure 18 A). This hydrogen-bond network is similar to the 
hydrogen-bond network identified in previous studies.74,76 In addition, we observed side-
chain hydrogen-bonding interactions of OE2 of Glu-41 as acceptor, and NE of Arg-76, 
NH2 of Arg-76, and NE2 of Gln-78 as donor with the dimannose (Figure 18 A), which 
was previously seen only in the case of trimannose binding.73 CVNmutDB retained all of 
the main-chain hydrogen bonds at Ala-42, Asp-44, Ser-52, Asn-53, and Lys-74; in 
contrast, all side-chain hydrogen-bonding interactions observed in P51G-m4-CVN were 
lost. Only one side-chain hydrogen bond, with OE1 of Glu-56 as acceptor, was observed 
for CVNmutDB. These results emphasize the critical role played by side-chain interactions 
of residues 41, 57, 76, and 78 in dimannose binding.
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Figure 18. Main chain hydrogen bond network and side chain hydrogen bond network for 
(A) P51G-m4-CVN (B) N42A (C) E41A (D) T57A and (E) N53S. The dimannose sugar 
is shown in cyan. The residues that form hydrogen bond with the sugar are shown in 
yellow and the hydrogen bond in magenta.
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 A comparison of the hydrogen-bond networks of the E41A, N42A, and T57A mutants 
with that of the P51G-m4-CVN-dimannose complex showed rearrangements in main-
chain and side-chain networks. Specifically, in N42A-dimannose, the main-chain 
hydrogen bond interactions of the nitrogen of Asn-42 and Asp-44 as donors, and oxygen 
of Lys-74 as acceptor were lost. The side-chain interactions of OE2 Glu-41, NE and NH2 
of Arg-76, and NE2 Gln-78 were lost; however, the side-chain interactions of OD1 
Asp-44 and OD1 Asn-53 were gained, preserving the interaction with OG1 of Thr-57 
(Figure 18 B). In E41A-dimannose, the main-chain carbonyl oxygen of Lys-74 as 
acceptor was lost and another oxygen of Ser-52 and Asn- 53 were gained as acceptors. 
The side-chain interactions of OE2 Glu-41, NE and NH2 of Arg-76, NE2 Gln-78, and 
OG1 of Thr-57 were lost, and OD1 Asp-44 and OD1 Asn- 53 were gained (Figure 18 C). 
The T57A mutant retained all of the main-chain hydrogen-bond interactions with 
dimannose; however, it lost all of the side-chain interactions except OD1 of Asp-44, 
which explains the slightly higher decrease in binding affinity as compared with the 
E41A mutant (Figure 18 D). E41G displayed a similar hydrogen-bond network (Figure 
19). The analysis shows that compared with the hydrogen-bond network of the P51G-m4-
CVN-dimannose complex, N42A lost the highest number of hydrogen bonds (most of 
which were backbone hydrogen bonds) to dimannose. The loss of hydrogen bonds in 
T57A and E41A corresponded mostly to side-chain hydrogen bonds. These findings 
suggest that the identity of the side chains at positions 41 and 57 plays a critical role in 
dimannose binding. Conversely, our results suggest that N42 defines the integrity (i.e., 
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the local stability) of the binding pocket by making critical side-chain-to-backbone 
hydrogen bonds to the neighboring β-sheet. Although polar-to-Ala mutations have 
disruptive effects on binding, we observe that conservative Asn to Ser mutation at 
position 53 preserves a hydrogen-bond pattern conducive to binding. The interactions of 
main-chain N of Asn-42, OE2 of Glu-41, OG1 of Thr-57, and NE2 of Gln-78 were lost, 
but additional side-chain interactions of N Asp-44, O of Ser-53, OD1 of Asp-44, and OG 
of Ser-53 were gained compared with P51G-m4-CVN-dimannose (Figure 18 E). Details 
of the hydrogen-bond analysis are provided in Table 5.
 One common approach in ensemble docking is to use snapshots of the MD 
trajectories.77,78 However, the success of this approach depends on whether the simulation 
covers the wide range of conformations sampled during binding. To gain a better idea of 
whether BP-Dock can help improve the binding affinity prediction beyond MD, we also 
performed ensemble docking using clustered snapshots of the REMD trajectories, and 
compared the results with those obtained by our flexible BP-Dock approach, which is 
based on a single mutant model. The binding affinities obtained from ensemble MD 
docking (Table 6) were all in the same range and could not really differentiate between a 
binder (i.e., N53S) and a nonbinder (N42A). Moreover, it did not capture the relative 
order of binding affinity (with N53S being the strongest, the binding score decreased in 
order from E41G to E41A and finally T57A, the weakest binder). However, BP-Dock 
approach captured the relative order of binding affinities observed experimentally and 
was capable of differentiating binders from nonbinders.
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Figure 19. The hydrogen bond network for (A) E41A and (B) E41G:dimannose complex. 
The dimannose sugar is shown in cyan. The residues that form hydrogen bond with the 
sugar are shown in yellow and the backbone hydrogen bond interactions are shown in 
magenta and side chain interactions in green.
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Table 5. Complete analysis of hydrogen bond network for P51G-m4-CVN and single 
point mutants for P51G-m4-CVN.
Backbone Side Chain
Residue Atom H-Bond Distance Role Residue Atom
H-Bond 
Distance Role
P51G-m4-
CVN
Asn42 N 3.097 DONOR Glu41 OE2 2.874 ACCEPTOR
Asn42 O 2.839 ACCEPTOR Thr57 OG1 2.827 ACCEPTOR
Asp44 N 2.922 DONOR Thr57 OG1 2.827 DONOR
Ser52 O 3.139 ACCEPTOR Arg76 NE 2.988 DONOR
Asn53 O 2.967 ACCEPTOR Arg76 NH2 2.871 DONOR
Lys74 O 2.984 ACCEPTOR Gln78 NE2 2.915 DONOR
CVNmutDB
Ala42 O 2.948 ACCEPTOR Glu56 OE1 3.269 ACCEPTOR
Ala42 N 3.146 DONOR
Asp44 N 2.872 DONOR
Ser52 O 2.998 ACCEPTOR
Asn53 O 2.792 ACCEPTOR
Lys74 O 3.043 ACCEPTOR
N42A
Ala42 O 3.083 ACCEPTOR Asp44 OD1 2.965 ACCEPTOR
Ser52 O 3.3 ACCEPTOR Asp44 OD1 2.729 ACCEPTOR
Asn53 O 2.883 ACCEPTOR Asn53 OD1 2.881 ACCEPTOR
ASN53 O 3.117 ACCEPTOR Thr57 OG1 2.959 ACCEPTOR
T57A
Asn42 O 2.976 ACCEPTOR Asp44 OD1 2.826 ACCEPTOR
Asp44 N 2.997 DONOR Asp44 OD1 3.476 ACCEPTOR
Asp44 N 2.997 DONOR
Ser52 O 2.983 ACCEPTOR
Asn53 O 2.804 ACCEPTOR
ASN53 O 2.805 ACCEPTOR
Lys74 O 2.758 ACCEPTOR
E41A
Asn42 N 3.201 DONOR Asp44 OD1 2.811 ACCEPTOR
Asn42 O 2.669 ACCEPTOR Asp44 OD1 2.97 ACCEPTOR
Asp44 N 3.216 DONOR Asn53 OD1 2.855 ACCEPTOR
Ser52 O 3.523 ACCEPTOR
Ser52 O 2.99 ACCEPTOR
Asn53 O 2.891 ACCEPTOR
Asn53 O 2.913 ACCEPTOR
E41G
Asn42 O 2.833 ACCEPTOR Asn42 OD1 2.931 ACCEPTOR
Asp44 N 3.227 DONOR Asn42 OD1 2.793 ACCEPTOR
Ser52 N 2.777 DONOR Thr57 OG1 2.915 ACCEPTOR
Ser52 O 2.828 ACCEPTOR Thr57 OG1 2.915 DONOR
Ser52 O 2.915 ACCEPTOR
Lys74 O 3.504 ACCEPTOR
N53S
Asn42 O 2.966 ACCEPTOR Asp44 OD1 2.774 ACCEPTOR
Asp44 N 3.115 DONOR Asp44 OD1 2.877 ACCEPTOR
Asp44 N 3.147 DONOR Ser53 OG 3.274 ACCEPTOR
Ser52 O 3.204 ACCEPTOR Ser53 OG 3.274 DONOR
Ser53 O 2.733 ACCEPTOR Arg76 NE 2.78 DONOR
Ser53 O 2.811 ACCEPTOR Arg76 NH2 2.689 DONOR
Lys74 O 2.857 ACCEPTOR
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Table 6. Comparison of Ensemble docking using MD snapshot vs BP-Dock cluster 
docking. The binding	  energy	  scores	  (Ebind)	  by	  X-­‐score	  and	  corresponding	  RMSDs	  of	  the	  ligand	  (RMSDligand)	  and	  protein side chain positions in the binding site 
(RMSDsidechain) for	  various	  CVN	  mutants	  are	  shown.	  Higher	  negative	  values	  indicate	  a	  higher	  binding	  af@inity	  prediction.
Protein
MD Ensemble Docking BP-Dock Cluster docking
RMSDligand
(Å)
RMSDsidechain
(Å)
X-Score
(kcal/mol)
RMSDligand
(Å)
RMSDsidechain
(Å)
X-Score
(kcal/mol)
N53S 0.14 1.238 -6.92 0.88 1.365 -7.06
E41A 0.22 1.511 -6.19 0.74 1.155 -6.7
E41G 1.51 1.059 -6.03 0.82 1.261 -6.82
N42A 1.16 1.835 -5.93 1.08 1.808 -5.37
T57A 1.59 1.124 -6.4 0.99 1.08 -6.46
 Our biophysical characterization by CD, thermal denaturation experiments, and 2D-
NMR showed that the N42A and T57A mutations slightly affected the stability of the 
protein. As observed in P51G-m4-CVN, N53S bound dimannose with dissociation 
constants in the low micromolar range and in intermediate exchange conditions, 
indicative of tight binding. On the other hand, a single point mutation of E41A, E41G, 
and T57A resulted in much weaker dissociation constants (in the low millimolar range) 
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and in fast exchange on the NMR timescale. However, mutation N42A abolished binding 
to dimannose.
 Overall, our experimental characterizations of these five mutants show that BP-Dock 
can capture the binding-affinity pattern. The X-Score binding energy scores suggest that 
the mutations of E41A, E41G, and T57A resulted in a lower binding affinity for 
dimannose compared with P51G-m4-CVN, indicating the critical role of these side chains 
in glycan recognition. Mutation N42A was more disruptive than the other mutations, with 
a binding score closer to that of the nonbinder CVNmutDB.
  1.3.6. Conclusions
 This work highlights the role of side-chain interactions in stabilizing the complex of 
dimannose and P51G-m4-CVN, with N42, T57, and E41 emerging as key factors for 
strong binding to dimannose. As shown here, N42 also appears to stabilize the binding 
pocket; its absence alters the hydrogen bond network within the protein and the ligand, 
thus abolishing binding. These effects add to other previously identified key interactions 
in CVN, such as the hydrogen bond networks with the side chain of Arg-7642,73 and the 
main-chain74, suggesting that a complex interplay between hydrogen bonds contributes to 
the remarkable affinity and specificity of CVN for α(1,2)-linked mannose.
 The experimental verification of flexible BP-Dock suggests that our approach could 
be utilized as an in silico screening tool to assess the effect of mutations on the binding 
affinity and specificity of CVN-based lectins as compared with the wt CVN.
53
 1.4. Nested Cyanovirin-N, A Covalent Dimer Construct
  1.4.1. Introduction
 The previous studies in our laboratory and others have shown that single-site binding 
mutants do not confer anti-viral activity. Having only either domain A (CVNmutDB)39 or 
domain B (P51G-m4-CVN)18 causes a significant decrease in binding affinity for gp120 
by ELISA and has no antiviral activity. Further studies have shown binding site mutants 
can have antiviral activity restored by dimerization. Two mutants used a hinge-region 
deletion or mutation to stabilize the domain-swapped dimer which had two domain B 
binding sites with domain A binding eliminated, ∆Q50-m4-CVN and S52P-m4-CVN, 
respectively.28 These mutants showed increased antiviral activity over the monomer 
counterpart, P51G-m4-CVN, suggesting multivalent interactions are required for antiviral 
activity. These results were further corroborated by disulfide-linked monomers of a 
domain A binding site mutant, [CVN∆A]ssd, and a domain-swapped dimer domain B 
binding site mutant stabilized by the ∆Q50 deletion, [CVN∆B]dsd, that restored the 
antiviral activity of their defective monomer counterparts.29 Through these studies, it was 
concluded that the multivalency of CVN is what confers antiviral activity.
 Expanding on the idea of multivalency leads to antiviral activity, other laboratories 
have attempted to control dimerization in order to increase the number of binding sites in 
hopes of increasing antiviral activity. Instead of using defective binding site mutants with 
dimer-stabilizing mutations, such as ∆Q50 of S52P, intact binding sites were combined 
with the dimer-stabilizing mutations to produce domain-swapped dimers with four 
binding sites.19 These domain-swapped dimers, [∆Q50]CVN and [S52P]CVN, were 
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found to have antiviral activity only comparable to that of wt CVN.19 It is very probable, 
though, that these mutants had similar antiviral activity to wt CVN due to their decreased 
stability compared to that of wt CVN. These results, along with the inability to control 
each binding site individually in a domain-swapped dimer, lead to these dimer mutants 
being insufficient to study the multivalency of CVN further.
 In order to better explore multivalency, the Mayo Laboratory designed covalent 
dimers of CVN by combining, in tandem, two CVN sequences with varying length 
polypeptide linkers.32 These CVN2Lx (where x is the number of amino acids in the linker) 
covalent dimers were shown to fold in a similar manner to the domain-swapped dimer by 
using partial carbohydrate binding site mutants and testing the antiviral activity. By 
including partial binding site mutants on one monomer sequence and the corresponding 
binding site mutations on the second monomer sequence, if the protein folded in a 
domain-swapped manner, the protein would not confer antiviral activity; and indeed, the 
antiviral assays showed this to be true.32 Interestingly, the fully intact covalent, tandem 
dimers, CVN2Lx, showed 3- to 6-fold enhancement of antiviral activity over the monomer 
of wt CVN.32 However, it is not clear whether or not the covalent, tandem dimer 
sequences would form higher order oligomers (domain swapping with other sequences 
for example) which could have a greater effect on the antiviral activity; although, 
increasing the number of CVN sequences linked in tandem did not confer higher antiviral 
activity.32
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  1.4.2. Background On Cyanovirin-N Homologous (CVNH) Family
 When CVN was discovered, it displayed a unique sequence and fold not yet found in 
other genes or proteins. Using sequence alignment and fold-prediction algorithms, a 
family of CVN homologous proteins, designated CVNH, was found in ferns and fungi.71 
Within this family, there were three types of proteins with similar predicted fold to that of 
CVN, as depicted in Figure 20. Type I CVNH are comprised of two tandem repeats of 
CVNH domains, while type II has one CVNH domain that is preceded by a portion of a 
mold specific gene of unknown function, MS8-h.71 Type III CVNH also have a MS8-h 
encoding region at the N-terminus, but are followed by a CVNH domain that is split by a 
LysM encoding region.71 The MS8 gene, of which part is found in Type II and III CVNH, 
is a sequence that encodes a predicted 21 kDa protein that is essential for proper hypha 
formation in pathogenic fungus.79 The LysM sequence is a Lysin Motif for a domain that 
recognizes glycans, peptidoglycans, and chitins; and is typically a domain within lysins, 
peptidoglycan hydrolases, peptidases, chitinases, esterases, reductases, and 
nucleotidases.80
 The Gronenborn laboratory has solved structures and study the function of a few 
CVNH proteins.38,76,81 These proteins, as predicted, display remarkable similarity to CVN 
overall, with differences occurring in loop regions and local, fine structure.38 All CVNHs 
with solved structures have also had at least one glycan binding site, albeit not as specific 
as the binding site of wt CVN.38,76 More interestingly, the type III CVNH, in which a 
LysM domain splits two 50 amino acid repeats of CVN, has also had its structure solved 
by NMR and still retains the binding function of both the CVN domain and the LysM 
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domain.81 As seen in Figure 21, the LysM domain (green) folds and enables the separated 
50 amino acid repeats of CVN (first repeat is blue, second repeat is yellow) to come back 
together and fold into a structure closely matching that of wt CVN. Interesting to note, 
the two domains behaved as two independent domains and the conserved glycine-rich 
linkers that link the N- and C-terminus of the LysM domain to the CVN domain were 
shown to be quite flexible.81
Figure 20. Schematic representation of the three types of the family of cyanovirin-N 
homologous proteins. Domains are labeled beneath the pictorial representation of the 
organization in each type. Type I consists of tandem repeats of CVNH (blue), whereas 
type II and type III are preceded by a partial MS8 gene (gray oval). Type III CNVHs have 
a LysM inserted between 50 amino acid repeats of CVNH (green).
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Figure 21. Structure of MoCVNH, a type III CVNH, from PDB ID 2I9Y.81 The first 50 
amino acid repeat of CVN is shown in blue, the LysM in green, the second 50 amino acid 
repeat of CVN in yellow, and the linkers in black, both in the structure and the domain 
representation beneath.
  1.4.3. Design of Nested Cyanovirin-N
 As previously suggested, dimerization and the geometry of the binding sites may be 
important in conferring antiviral activity, see Figure 6, panel b.32 Disulfide-linked 
monomers may not increase the antiviral activity of CVN due to the lack of meeting 
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probable geometric requirements. The end-to-end, tandom-linked dimers designed by the 
Mayo group most likely meet these geometric requirements, but domain-swapping with 
other units of CVN to create higher order oligomers is very possible and likely at higher 
concentrations.31,32 In order to further study multivalency and to design a dimer with 
higher antiviral activity, we aim to design a covalent dimer in which we can control each 
binding site individually.
 Nested CVN was designed on the basis of type III of the CVN homologous family.71 
Using the idea that a full-length CVN sequence could be interrupted, by LysM in the case 
of type III CVNH, and still fold in a manner that still binds glycans, Nested CVN 
replaces the LysM domain with another full sequence of CVN, utilizing the same glycine-
rich linkers found in type III CVNH, as shown in Figure 22. Constructs were originally 
designed to include the “P51G” corresponding hinge region mutation in the CVN insert; 
however, there is recent evidence suggesting the P51G mutation causes a decrease in 
binding affinity for dimannose (unpublished data). For this reason, the wild hinge region 
(Nested-P CVN) was introduced back into the insert to test both constructs.
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Figure 22. Nested CVN model and sequence are shown. The CVN insert is shown in 
blue, following the C-terminus of the first 50 amino acid repeat (orange) and preceding 
the N-terminus of the second 50 amino acid repeat (blue). Each region is connected by a 
glycine-rich linker, show in black. The sequence of Nested CVN is shown with the 
corresponding “P51” position in the hinge region of the insert highlighted in red.
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  1.4.4. Materials and Methods
 Genes with the corresponding sequences with pelB leader sequences preceding were 
ordered from GenScript (Piscataway, NJ) and double digested with NdeI and XhoI. 
Inserts were ligated into pET26b(+) vectors following the Novagen pET system manual. 
The vector was transformed into NEB5α cells and BL21 cells from New England 
Biolabs, Inc. (Ipswich, MA). The protein was expressed from BL21 cells by inoculating 
10 mL Luria-Bertani (LB) medium with incubation at 37˚C and shaking at 250 rpm. The 
cells were grown overnight and then added to 1 L of fresh LB medium. The culture was 
incubated at 37˚C and 250 rpm shaking until an OD600 of approximately 0.8. Protein 
expression was induced with 0.4 mM final concentration of isopropyl β-D-
thiogalactoside (IPTG) and 20 mM benzyl alcohol. Incubation and shaking of the cell 
culture was continued overnight at 20˚C. When the culture reached an OD600 of 1.3-1.5, 
cells were harvested by centrifugation at 6,000 rpm for 10 minutes. 
 The periplasmic fraction was collected by resuspending the cell pellet into 30 mM 
Tris, 20% sucrose, 0.5 mM EDTA, pH =7.5 with stirring at room temperature for 10 
minutes. The cells were pelleted by centrifuging at 10,000 rpm at 4˚C. The cells were 
resuspended in ice cold 5 mM MgSO4 by stirring on ice for 20 minutes. The cells were 
once again pelleted by centrifugation at maximum speed for 10 minutes, and the 
supernatant was saved as the periplasmic fraction. The cytoplasmic fraction was collected 
by sonicating the cells on ice for a total of 20 minutes. This suspension of broken cells 
was then centrifuged at 15,000 rpm for 20 minutes, saving the supernatant to check for 
target protein in SDS-PAGE Tricine gels. The pellet of broken cells was resuspended in 
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100 mM Tris pH=7.5, 2 M urea to wash away any unwanted proteins. The suspension 
was centrifuged at 15,000rpm for 20 minutes. The 2 M urea wash was repeated until the 
supernatant was clear after centrifugation. The broken cells were rinsed by suspension in 
100 mM Tris and centrifuged at 15,000 rpm for 20 minutes. To collect the any inclusion 
bodies, the broken cells were dissolved in denaturing conditions, 8 M urea, 20 mM Tris, 
20 mM imidazole, and 0.5 M NaCl, pH = 7.5, and centrifuged at 16,500 rpm for 45 
minutes. The supernatant was collected, and all fractions were analyzed by Tricine SDS-
PAGE for target protein.
 Once the target protein was located, the supernatant was filtered and loaded onto a 
nickel sepharose column (Ni Sepharose High Performance medium from GE Healthcare). 
The protein was eluted off the column using 400 mM imidazole under native conditions. 
A Tricine SDS-PAGE gel was performed to determine the fractions in which the target 
protein was located. To confirm the correct molecular weight of the protein, the protein 
was run on MALDI-TOF mass spectrometry, using sinapinic acid matrix. Protein 
concentrations were determined by measuring tryptophan absorbance at 280 nm using an 
extinction coefficient of 19,540 M-1 cm-1. The yield of protein was approximately 10 mg 
protein per liter of LB medium.
 Circular dichroism was utilized to estimate secondary structure and as a preliminary 
measure to check protein folding. All measurements were performed using a Jasco J-815 
spectropolarimeter equipped with a thermostatic cell holder, PTC 424S. Spectra were 
measured from 240 nm to 190 nm, using a scanning speed of 50 nm/min and a data pitch 
of 1.0 nm at 15˚C.82 A 0.1 cm quartz cell was used, with protein concentrations at 
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approximately 15 µM in 10 mM HEPES, pH = 8.0 buffer. Thermal denaturation studies 
were also performed by taking full spectra using the previous settings at approximately 
every 2˚C from 4˚C to 90˚C. Detailed thermodynamic analysis was precluded due to the 
irreversible unfolding of Nested CVN, which matches that of wt CVN. Apparent Tm was 
determined by fitting the data to equation 5:
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 Enzyme-linked immunosorbent assays (ELISA) were utilized to probe how tightly the 
Nested CVN constructs bound to soluble gp120 (sgp120) compared to wt CVN. The 
experiment was performed as previously described.9 In summary, each well except for the 
last column of 8 wells, of a 96-well plate (Nunc; Maxiscorp, Gaithersburg, MD) was 
incubated with 100 ng of gp120 in phosphate buffered saline (PBS) for two hours at room 
temperature. The plates were then rinsed with PBS containing 0.1% Tween 20 (PBST) 
three times. The plates were then blocked with 3% bovine serum albumin (BSA) at 4˚C 
overnight. The plates were then washed three times with PBST. Half log serial dilutions 
of Nested CVN, Nested-P CVN, and wt CVN were then added to the wells in triplicate, 
for final concentrations ranging from 0.005 nM to 0.05 µM. The last column was left as a 
blank, and only contained the BSA. The plates were incubated for one hour, and then 
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washed three times with PBST. Each well was then incubated anti-CVN rabbit polyclonal 
antibody (final concentration of 10 µg/mL) for 1 hour and then washed with PBST. The 
plates were then incubated with a secondary anti-rabbit IgG antibodies conjugated to 
horseradish peroxidase (Sigma, St. Louis, MO) for 1 hour. The plates were then washed 
again three times with PBST. 100 µL of tetramethylbenzidine peroxidase substrate was 
then added to each well and allowed to react for approximately 2 minutes until a blue 
color was observed. The reaction was then quenched with 50 µL of 2 M H2SO4, and the 
absorbance at 450 nm was recorded.
 Anti-HIV activity assay of Nested CVN and Nested-P CVN were performed at NCI-
Fredericksburg. In short, a modified XTT assay was utilized to determine the anti-HIV 
activity of Nested CVNand Nested-P CVN, alongside a recombinant CVN (rCVN) that 
was provided by NCI-Fredericksburg. Experimental procedure involved plating 
uninfected CEM-SS cells at a density of 1 x 10-5 cells/mL in 50 µL of complete medium 
in a 96-well plate. Serial dilutions of 100 µL of rCVN, Nested CVN, and Nested-P CVN 
were added to the wells. The cells were then infected with 50 µL of HIV-1RF virus. The 
plates were incubated at 37˚C in an atmosphere containing 5% CO2 for 6 days. To 
estimate cellular viability, 50 µL XTT solution was added to each well and incubated for 
4 hours at 37˚C. Cells that had not been infected with the HIV virus could reduce XTT to 
a soluble, colored formazan while HIV-infected cells could not. Metabolic reduction of 
XTT to formazan was recorded by absorbance at 450 nm to determine cellular viability.83
 Isothermal titration calorimetry (ITC) was utilized to ensure that binding sites were 
still intact and had high affinity for dimannose. To this end, samples were sent to 
64
Sanford-Burnham Medical Research Institute. In short, 3.6 mM dimannose was titrated 
into 100 µM Nested CVN samples in 20 mM HEPES for high affinity binding site 
determination, while the low affinity binding site utilized 20 mM dimmanose. Data was 
fit using common procedures, allowing number of binding sites as a fitting parameter. In 
some cases, the number of binding sites had to be fixed at four (or two in the case where 
the high affinity set and low affinity set binding Kd were determined in separate 
experiments) in order to obtain a proper fitting.
  1.4.5. Biophysical Characterization
 Using the pelB/pET expression system, soluble protein yields were routinely around 
10 mg per liter of broth. To show that target protein was over-expressed, SDS-PAGE was 
run on pre-induction and post-induction samples (lanes 2 and 3 in Figure 23). SDS-PAGE 
was also utilized to make sure the protein was localized in the perisplasmic fraction. To 
ensure the proper fractions were collected for further characterization, and as a 
preliminary check of purity, SDS-PAGE was utilized again. Figure 23 shows a typical 
gel, and only fractions that were deemed to have high amounts of target protein with no 
or little impurities were used for dialysis and further characterization.
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 Figure 23: Tricine SDS-PAGE gel of Nested CVN. Important molecular weight markers 
are labeled in which the calculated weight of Nested CVN appears between. Lane 1 - 
Mark 12 Unstained standard (Life Technologies); Lane 2 - pre-induction; Lane 3 - post-
induction; Lane 4 - sucrose wash; Lane 5 - cytoplasmic fraction; Lane 6 - periplasmic 
fraction; Lane 7 - inclusion bodies.
 
 To verify that the Nested CVN and Nested-P CVN were expressed correctly, a more 
accurate molecular weight determination needed to be performed. MALDI-TOF was 
performed, using sinapinic acid as the matrix, for both Nested CVN and Nested-P CVN. 
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Nested CVN, was verified by a calculated molecular weight of 24,423 Daltons and 
Nested-P CVN, was verified by a calculated molecular weight of 24,463 Daltons. Every 
expression of both proteins’ molecular weights was always verified by MALDI-TOF 
before any further characterization.
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Figure 24: Overall CD spectra of Nested CVN (blue) and Nested-P CVN (red) measured 
at 4˚C.
 To ensure that the Nested constructs were properly folded, circular dichroism was 
utilized to make inferences about the secondary structure and the resulting spectra were 
compared to previous spectra of wt CVN. Figure 24 shows the overall CD spectra of 
Nested CVN and Nested-P CVN. The spectrum for the protein has minimum at 
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approximately 212 nm and a maximum around 192 nm. The spectrum mostly resembles a 
β-sheet protein, which is to be expected since the majority of Nested CVN is β-sheet.
 To show that the Nested constructs were stable proteins, a thermal denaturation 
experiment was performed. Figure 25 shows the fraction folded versus temperature at a 
wavelength of 235 nm for both constructs. Commercially available software (Prism 6, 
GraphPad Software) was used to fit the sigmoidal curves and determine the midpoint for 
the melting points of Nested CVN and Nested-P CVN. The average melting point from 
the two wavelengths used was 56.3˚C, which is stable compared to that of wt CVN at 
59.0˚C.28 
 Nested CVN’s and Nested-P CVN’s interaction with gp120 were measured using 
ELISA. Wild type CVN was also used, for comparison and as a control as binding to 
gp120 has been previously described.9 The results are shown in Figure 26.
 The data was fit using commercially available software as described earlier, using the 
Hill-Slope model. EC50 for Nested CVN was determined to be 3.47 x 10-10 M ± 0.33 x 
10-10 M. Nested CVN without histag gave similar results (data not shown). EC50 for wt 
CVN was determined to be 3.33 x 10-9 M ± 0.23 x 10-9 M. This is a worse EC50 for wt 
CVN than is typically observed, but highlights some of the shortcomings in 
reproducibility of ELISA experiments. The data for the EC50 of these constructs of CVN, 
along with other mutants, is summarized in Table 7.
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Figure 25: Thermal denaturation curves for Nested CVN (blue) and Nested-P CVN (red). 
The plots follow the wavelength 235 nm and the data was fit using Prism 6 from 
GraphPad Software. The Tm for Nested CVN and Nested-P CVN were 59.0˚C and 
56.3˚C, respectively. These variants of CVN are stable, similar to wt CVN.
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Figure 26: ELISA results of the binding of wtCVN (red circles) and Nested CVN (blue 
diamonds) to gp120. Serial dilutions of proteins were added to plates coated with gp120 
(100 ng/well). For both proteins, polyclonal rabbit anti-CVN antibodies were used to 
detect bound proteins followed by incubation with anti-rabbit IgG-Peroxidase antibodies; 
the peroxidase catalyzed oxidation of TMB substrate was monitored at 450 nm.
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Table 7: Binding of CVN mutants to HIV gp120
Mutant EC50, nM
Nested CVN 0.347
wt CVN A 0.1
P51G-m4-CVN B 173
∆Q50-m4-CVN B 23
S52P-m4-CVN B 9.6
m4-CVN A 0.6
A From reference 18.
B From reference 28.
 To evaluate the anti-HIV activity of the Nested constructs, a modified XTT-
tetrazolium assay was performed. Nested CVN and Nested-P CVN were tested against 
rCVN. The results of the assay and the fits used to determine the EC50 are shown in 
Figure 27.
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Figure 27: Anti-HIV activity of Nested CVN and wt CVN. Logistic fitting in OriginPro 
to provide the fit and determine the EC50 was used. The bottom boundary of the logistic 
fit was fixed at the percent control of cells that had only virus added, without any 
inhibitors. The value for Nested CVN EC50 was determined to be 2.60 x 10-10 ± 0.59 x 
10-10 M and for CVN was determined to be 7.41 x 10-11 ± 3.99 x 10-11 M.
 The values determined for the EC50 in the anti-HIV activity of Nested CVN and wt 
CVN are summarized in Table 8, along with other mutants that have been tested for anti-
HIV activity. It is clear that Nested CVN has comparable anti-HIV activity to rCVN, 0.26 
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nM versus 0.07 nM, respectively. The rCVN anti-HIV activity is a little stronger than 
typically reported for wt CVN, but is still comparable.
Table 8: Anti-HIV activity of Nested CVN and other mutants
Mutant EC50, nM
Nested CVN 0.26
wt CVN A 0.9
P51G-m4-CVN B >>5,000
∆Q50-m4-CVN B 320
S52P-m4-CVN B ≈3000
m4-CVN A 240
A From reference 18.
B From reference 28.
 To gain further information about the binding sites and the affinity for dimannose of 
Nested CVN and Nested-P CVN, isothermal titration calorimetry was performed at 
Sanford-Burnham Medical Research Institute. The data and fits are shown in Figure 28. 
In short, the data could be fit with by using a 2 x 2 binding site model; which is expected. 
Nested CVN had two high affinity binding sites with a Kd of 24.5 µM ± 1.8 µM and two 
low affinity binding sites with a Kd of 952 µM ± 7.9 µM; while Nested-P CVN had two 
high affinity binding sites with a Kd of 15.7 µM ± 1.2 µM and two low affinity binding 
sites with a Kd of 1420 µM ± 16 µM.
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Figure 28. ITC data from Nested CVN (A.) and Nested-P CVN (B.) titrated with 
dimmanose.
  1.4.6. Discussion
 Nested CVN and Nested-P CVN has provided insight into the interaction of Nested 
CVN with gp120 and the role in anti-HIV activity. As a designed covalent dimer, it offers 
insight into the role of dimerization and multivalency. All data is summarized in Table 9. 
With the procedure described above, we have routinely been able to produce 30 mg of 
protein per 500 mL broth. The protein was shown to be fairly stable, in that the melting 
temperature was found to be 55˚C.
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Table 9: Summary of all mutant data
Mutant state Tm (˚C) EC50 binding to gp120 (nM)
EC50 antiviral 
activity (nM)
wtCVN wild type 58 0.1 0.9
m4-CVN
domain A binding 
mutant 46 0.6 240
P51G-m4-CVN
monomer, domain A 
binding mutant 64 173 >>5000
∆Q50 -m4-CVN
dimer, domain A 
binding mutant 32.5 23 320
S52P-m4-CVN
dimer, domain A 
binding mutant 39.5 9.6 ~3000
Nested CVN covalent dimer ~58 0.423 423
 With the results presented here, it is evident that we designed a covalent dimer of 
cyanovirin-N, which has comparable potency the wild type protein in binding to gp120 
and in antiviral activity assays. In our ELISA study, our findings for Nested CVN binding 
to gp120 were equivalent to that of wt CVN. Previous reports of wt CVN have an EC50 of 
approximately 0.1 nM, while our study showed an EC50 approximately one-fold higher.9 
However, we do believe that this shows that Nested CVN binds gp120 at least as well as 
wt CVN.
 While previous studies have shown that only two binding sites are required for 
antiviral activity, we show here that four binding sites may change the way in how the 
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protein binds to gp120 of the Env of HIV.28 In the case of antiviral activity, it is evident 
that Nested CVN inhibits HIV fusion differently than wt CVN based on the Hill 
coefficient of the plot. Nested CVN displays a Hill coefficient of 2.52, while wt CVN has 
a Hill coefficient of 0.53. Nested CVN then shows cooperative binding in that when one 
binding site binds, it increases the binding of the next binding site. This is expected, since 
the molecule is a covalent dimer with four binding sites, when one site binds, the next 
binding site is already in close proximity to another Manα(1-2)Manα moiety.
 The ITC results suggest that all the binding sites are intact and bind dimannose for 
both Nested CVN and Nested-P CVN. The low micromolar value for the high affinity 
binding site matches that of wt CVN ITC values obtained by our group (data not shown). 
The low affinity binding site for the two Nested constructs are approximately 1 mM 
which is about two times higher than observed by our group for wt CVN (data not 
shown). Unfortunately, ITC data cannot unequivocally show that all four binding sites are 
intact as the data for Nested-P CVN can also be fit with one low affinity binding site.
 In conclusion, previous mutants of Cyanovirin-N have been used to show that 
multivalency is needed to confer anti-HIV activity.18,28 Here, we have shown that 
covalent dimer of CVN is as stable and as effective at binding to gp120 and in antiviral 
activity assays. It is also evident that it changes the interactions with the Env protein in 
antiviral activities, as reflected by the Hill coefficient. Multivalency is required for 
antiviral activity, and in this study, we show that a covalent dimer that is multivalent 
confers comparable results to that of wild-type cyanovirin-N.
76
2. WW Domain
 2.1. Introduction
 WW domains are a conserved module of 32-40 amino acids found in many different 
proteins and provide signaling, regulatory, and cytoskeletal function.84-87 Many studies 
show that the WW domain recognizes proline-rich peptide regions of larger proteins.88-91 
Due to the computational and experimentally facile nature of the WW domain, the 
Ranganathan group used WW domains as a model system to study and create artificial 
sequences using statistical coupling analysis (SCA) and multiple sequence alignment 
(MSA).92 By randomly selecting amino acids at each site from natural WW MSA, the 
group created a series of sequences they termed IC sequences (site-independent 
conservation).92 These IC sequences are built randomly, ignoring any statistical coupling. 
Using Monte Carlo simulation, the group also created a series of sequences which took 
into account statistical coupling they observed from the SCA; they termed these CC 
sequences (couple conservation).92 The CC sequences were built taking into account that 
some positions coevolved with other positions. Using the natural, IC, and CC sequences, 
the Ranganathan group determined which sequences would fold by expression tests in E. 
coli and then further experiments using 1H-NMR and fluorescent thermal denaturation 
studies.92 Using these methods, the Ranganathan group showed that coupled conservation 
(pairwise coevolution) was important as some of the designed CC sequences would fold, 
while none of the IC sequences folded into WW domains.92 Indeed, the structure of one 
of their designed sequences, CC45, was solved and showed to have the similar fold to 
that of two natural WW domains.92 In a concurrent paper, the Ranganathan group also 
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showed that some of their designed sequences maintained function in that they would 
bind proline-rich peptides.93
Table 10. Organization of the WW domain sequences. N, native; CC, coupled 
conservation; and IC, site-independent conservation, sequences were grouped into 
foldable sequences if they were expressed solubly and a Tm or unfoldable sequences if 
they were expressed solubly but did not have a Tm.92
N CC IC Total
Foldable 28 12 0 40
Unfoldable 0 19 30 49
 Using the sequences generated in the Ranganathan group paper, we collaborated with 
Dr. Ozkan’s group to try to further determine the folding requirements encoded in natural 
sequences.92 While the Ranganathan paper only considered statistical information in the 
sequence space, we aim to use tertiary structural information as well to explore the 
sequence-structure relationship in WW domain proteins. To this end, we used simulation 
data provided by zipping and assembly method (ZAM) and a contact probability metric 
(CPROB) to determine the difference between folders (those sequences that folded) and 
nonfolders (those sequences which were expressed and soluble, but did not fold into 
WW domains).94,95 Our collaborators excluded the sequences from the Ranganathan 
study that were insoluble or poorly expressed because the reasons for poor expression 
and insolubility were beyond the scope of our study. From the remaining sequences, our 
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collaborators grouped the sequences into foldable and unfoldable sequences, those 
sequences deemed folded showed thermal denaturation profiles and 1H-NMR spectra 
evident of the native state. Table 10 summarizes the sequences used in this study.
 All the WW domain sequences in Table 10 were simulated using ZAM. ZAM is a 
method which simulates folding with small fragments of the sequences in silico and 
growing the fragments into the full sequence.94 For the purpose of our study, 8-mer 
fragments were used. From these simulations, the contact probability (CPROB) within an 
8-mer fragment was determined as the calculated fraction of sampled configurations with 
inter-residue distance less than 8.0 Å.96 Using this data, a classification model was 
developed by our collaborators, and maximum likelihood contact probability 
(MLCPROB) maps were created, shown in Figure 29. From this data, the difference in 
contact probability between folded and unfolded sequences shows that there are five 
crucial contacts that exist in the simulated folding of WW domains. To show these 
contacts are crucial, unfolded sequences were simulated with these contacts artificially 
forced in silico; and through the simulation the unfolded sequences would fold into WW 
domain-like structures with these forced contacts (data not shown). To further verify 
these results, we checked for the crucial contacts in the ZAM simulated structures of 
unfolded and folded sequences. Table 11 shows that with relatively high efficiency, we 
can predict folded and unfolded sequences based on the five crucial contacts.
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Figure 29. MLCPROB maps for 8-mer fragments for foldable sequences (A), unfoldable 
sequences (B), and the difference map of unfolded sequence MLCPROB from folded 
sequence MLCPROB. Figure courtesy of Taisong Zou.
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Table 11. Predicted versus observed folded and unfolded WW domain sequences.
Predicted
Observed unfolded folded percent correct
unfolded 41 8 83.7
folded 9 31 77.5
 In order to show these crucial contacts are enough to lend tendency of WW domains 
to fold, we aim to introduce these contacts into an unfolded sequence. To this end, our 
collaborators tested introducing native contacts in silico to unfolded sequences. In this 
way, hybrid sequences were generated and tested for their Pfold, their probability of 
folding. Shown in Figure 30 is the method in which we generated a hybrid sequence 
CC16_N21 that has a high probability of folding. Sequences with the highest probability 
of folding and showing a WW domain-like fold from the in silico simulations were 
chosen to experimentally test whether these sequences would fold into WW domains and 
retain the function of WW domains, that is their binding affinity for proline-rich peptides.
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Figure 30. Method for generation of the hybrid sequence CC16_N21. Those 
combinations of contacts at the crucial points that gave the highest Pfold were chosen for 
insertion into the CC16 sequence. Below the scheme are the sequences of the unfolded, 
folded, and hybrid sequence. Pairs of contacts that were changed are highlighted in 
corresponding colors.
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 2.2. Materials and Methods
 WW domain peptides and group I peptides were synthesized using standard solid 
phase peptide synthesis (SPPS) protocols.97 In short, peptides were synthesized using 
Rink Amide-ChemMatrix® (Matrix Innovations) on a CEM Liberty automated peptide 
synthesizer with 9-fluorenylmethoxycarbonyl(FMOC)-protected amino acids. 
Dimethylformamide (DMF) was used as the solvent, 20% piperdine with 1% HBTU (O-
Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate) was used for 
deprotection, 0.40 M HOBt (N-hydroxy benzotriazole) in DMF was used for activation, 
and 35% N-Methyl-2-pyrrolidone (NMP)/65% N,N-Diisopropylethylamine, or Hünig's 
base (DIPEA) used for coupling. Peptides were deprotected and cleaved in one step with 
95% trifluoroacetic acid (TFA), 2.5% water, 2.5% triisopropylsilane (TIS). After reducing 
volume by evaporation under nitrogen, crude peptide was precipitated with cold ether and 
purified by reverse phase HPLC on an Agilent C18 column. MALDI-TOF analysis was 
used to verify the molecular weight of the peptides.
 15N-labeled peptides were expressed as fusion proteins with maltose binding protein 
using the pMAL-c5x vector (New England Biolabs). In short, the WW domain peptide 
sequence preceded by DNA encoding a six histidine tag and a TEV cleavage site was 
ordered from GenScript with BamHI and NdeI restriction sites for insertion into the 
pMAL-c5x vector. After double digestion with BamHI and NdeI and purification of the 
insert and vector with a 1% agarose gel, the insert was ligated into the vector with a 
ration of 3:1 insert:vector and transformed into NEB 5-alpha competent cells. The 
transformed cells were cultured and plasmids isolated and sequenced at the DNA 
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Laboratory at ASU using the forward primer 5’-
d(GGTCGTCAGACTGTCGATGAAGCC)-3’ and reverse primer 5’-
d(TGTCCTACTCAGGAGAGCGTTCAC)-3’. Correct plasmids were transformed into 
BL21 cells (New England Biolabs) for expression. Fusion proteins were expressed by 
inoculating 10 mL Luria-Bertani (LB) medium with incubation at 37˚C and shaking at 
250 rpm. The cells were grown overnight and then added to 1 L of fresh LB medium. The 
culture was incubated at 37˚C and 250 rpm shaking until an OD600 of approximately 0.8. 
Protein expression was induced with 0.4 mM final concentration of isopropyl β-D-
thiogalactoside (IPTG) and 20 mM benzyl alcohol. Incubation and shaking of the cell 
culture was continued overnight at 37˚C. When the culture reached an OD600 of 1.3-1.5, 
cells were harvested by centrifugation at 6,000 rpm for 10 minutes. The cytoplasmic 
fraction was isolated by resuspension of the cell pellet in 100 mM Tris, pH=7.5 and 
sonicating the cells on ice for a total of 20 minutes. This suspension of broken cells was 
then centrifuged at 15,000 rpm for 20 minutes, saving the supernatant as the cytoplasmic 
fraction. The fusion proteins were purified by nickel affinity chromatography. Fractions 
containing the fusion protein were treated with histidine-tagged TEV protease and ran 
over a nickel column again, this time collecting the fraction that did not bind. MALDI-
TOF analysis verified the molecular weight of the WW domain peptide.
 Circular dichroism measurements were utilized to determine the fold and stability of 
the proteins. Full scans were acquired on a JASCO J-815 CD spectrometer (JASCO , 
Easton, MD) from 260-190 nm at 4˚C in a 1 cm cuvette with protein concentrations at 1 
µM (or 1 mM cuvette and 20 µM protein concentration) after overnight equilibration at 
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4˚C in 20 mM sodium phosphate, pH 7. Thermal denaturation experiments were 
performed by following molar ellipticity at 227 nm between 4-90˚C with heating at 1˚C/
minute. In the cases where a folded and unfolded baseline were clearly established, data 
were fitted using equation 6:
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where mf and bf are the slope and intercept of the folded baseline, respectively, and mu 
and bu are the slope and intercept of the unfolded baseline, respectively. In the cases 
where a folded or unfolded baseline could not be established, Tm were estimated by fitting 
the differential melting curve using the van’t Hoff relationship.98 In short, the algebraic 
derivative was taken of the CD signal, plotted against temperature in Kelvin, and fit to 
equation 7:
∂θ
∂T = Af (1− f )(T
2 )
 (7)
where A is scaling factor and 𝑓  is  substituted  with  equation  8:
f = KK +1   (8)
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and  5inally,  Tm  is  determined  by  substituting  equation  9  for  K:
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 (9)where  ∆HvH  is  the  transition  enthalpy  and  R  is  the  gas  constant.  The  data  were  5it  using  Prism 6 from GraphPad Software.
 For binding studies, samples were sent to Sanford-Burnham Medical Research 
Insititude (La Jolla, CA). In short, aliquots of group I peptide from a5 mM stock was 
titrated into 100 µM WW domain peptide, in 20 mM phosphate buffer, pH 7. Data were 
fit using standard fitting procedures with a one binding site model.
 2.3. Results
 Through the biophysical modeling, five local contacts were predicted to be enough 
predict foldable sequences. Using this finding, foldable sequences were designed from 
unfolded sequences by introducing native contacts at those positions. The most promising 
of these designed sequences was CC16_N21, and this sequence was chosen for 
biophysical characterization.
 Thermal denaturation studies were performed on the native WW domain sequence, 
N21, as a positive control, and of the designed sequence, CC16_N21. After verifying the 
full circular dichroism spectrum of each peptide had the stereotypical maximum at 
approximately 227 nm, Figure 31, proteins were melted from 4˚C to 90˚C following the 
loss of CD signal at 227 nm, Figure 32. Fitting the denaturation of N21 to a two-state 
model, Equation 6, gives a Tm of 55˚C. Since the folded baseline of N21 has a strong 
negative slope, the two-state unfolding model may be inappropriate. 
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Figure 31. CD spectra of N21 (blue squares) and CC16_N21 (red circles) collected at 
4˚C. Both spectra indicate folded WW domains at 4˚C due to the peak at 227 nm.
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Figure 32. Thermal denaturation curves of N21, blue squares, and CC16_N21, red circles. 
Due to the lack of a stable, folded baseline, the data was unable to be fit using a two-state 
unfolding model.
 Using the van’t Hoff approximations outlined in the materials and methods of this 
chapter, the differential melting curve (smoothed by averaging 4 neighbor points for 
clarity sake) of N21 was fitted to Equations 7-9, as shown in Figure 33 to gain a better 
estimation of the Tm of each peptide.98 The differential melting curve suggests two 
separate melting transitions, due to the two minimums in the plot. However, determining 
the unfolding mechanism of the native peptide is beyond the scope of this study. In order 
to get a better estimate of the Tm, only the large, final transition was fit to the differential 
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melting curve/van’t Hoff model, Figure 34. This gives an apparent Tm of 42.5˚C for N21. 
CC16_N21 thermal denaturation data was fit using the differential melting curve/van’t 
Hoff model, as well, since the protein began to melt immediately, as seen in Figure 32. 
The differential melting curve/van’t Hoff fitting for CC16_N21 is shown in Figure 35, 
and gives the an apparent Tm of 18.6˚C.
Figure 33. Differential melting curve of N21.There are two minima in the spectra, 
suggesting that N21 does not follow a two-state model.
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Figure 34. Differential melting curve of N21 showing the large transition with fitted line. 
The fit gives an apparent Tm of 315.5 K (42.5˚C).
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Figure 35. Differential melting curve of CC16_N21 and fit is shown. The apparent Tm for 
CC16_N21 is 291.6 K (18.6˚C).
 The binding affinity for group I peptides was determined by ITC, by titrating in a 
model group I peptide, EYPPYPPPPYPSG, into CC16_N21 at 4˚C. The titration was 
completed in duplicate, and the fitting allowed the number of binding sites to be a fitting 
parameter. The number of sites was given was found to be 1.23 for both titrations, 
suggesting only one binding site, as expected. The average Kd was found to be 71.0 µM ± 
4.7 µM. The fits are shown in Figure 36.
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Figure 36. ITC of the group I peptide, EYPPYPPPPYPSG, into CC16_N21. Fitting of the 
data suggests one binding site and duplicate titrations give 73.5 µM ± 4.4 µM and 68.5 
µM ± 5.0 µM, suggesting the designed CC16_N21 retains the function of WW domains.
 2.4. Discussion and Conclusion
 After characterizing the WW domains as foldable and unfoldable through ZAM, and 
comparing the contact probability of the folded sequences and unfolded sequences, five 
crucial contacts were determined.96 By forcing the contacts in unfolded sequences 
artificially in silico and folding through ZAM, unfolded sequences were found to fold 
artificially. Utilizing this idea, a foldable sequence was designed from an unfolded 
sequence by introducing contacts from a native sequence into the unfolded sequence. The 
most promising sequences were synthesized by solid phase peptide synthesis. The most 
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promising sequence, CC16_N21, showed a folded CD spectra at 4˚C and matched closely 
to that of the native sequence (Figure 31). Compared to unfolded sequences (data not 
shown), the design of CC16_N21 was able to rescue the fold and some of the stability of 
that of the native sequence, N21 (Figure 31 and Figure 32). 
 Due to the lack of a folded baseline in the thermal denaturation, the differential 
melting curve was obtained by taking the algebraic derivative of the CD signal.98 The 
differential melting curve was then fit to equations 7, 8, and 9 to estimate the melting 
point of the native sequence peptide, N21 in Figure 34, and the designed sequence 
peptide, CC16_N21 in Figure 35.92,98 While N21 was found to have a moderately stable 
Tm of 42.5˚C, the lack of a true folded baseline suggests this native sequence is not truly 
that stable. Also, in the differential melting curve of N21 (Figure 33), there are two 
minimum suggesting not a true two state melting pathway. While determining the melting 
pathway of N21 is outside the scope of this study, the ambiguity of the melting point 
gives credence to our designed peptide, CC16_N21, rescuing the fold and a majority of 
the stability of the native sequence.
 In order to further show that CC16_N21 was a proper WW domain peptide, 
functional studies were performed. To this end, ITC titrations with a group I peptide, 
EYPPYPPPPYPSG, were performed. With the low stability of CC16_N21, an apparent 
Tm of 18.6˚C, all experiments were performed at 4˚C. Fitting the titration showed good 
agreement with one binding site, and gave an average Kd of 71 µM. This Kd is on the 
same order of magnitude as other native WW domains and designed WW domains.93 
Given the functional aspect of CC16_N21, and similar fold and stability to native 
93
sequences, we have shown here the design of a foldable WW domain sequence from an 
unfoldable sequence by introducing native or stabilizing interactions at five crucial 
contacts.
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